[{"file": "1601.07127.tex", "nexttext": "\nwhere $\\beta_{1,1}$ and $\\beta_{1,2}$ represent the incremental costs and QALYs respectively.  The distribution of the errors $\\mathcal{F}$ is not assumed to be normal.\n\nIn addition to reporting incremental costs and  QALYs, CEA often report the INB, defined as\n$\\mbox{INB}(\\lambda) = \\lambda \\beta_{1,2}-\\beta_{1,1}$, where  $\\lambda$ represents the decision-makers {\\it willingness to pay} for a one unit gain in health outcome. Thus the new treatment is cost-effective if $\\mbox{INB}>0$. \\footnote{For a given $\\lambda$, the standard error of INB can be estimated from the estimated increments $\\hat{\\beta}_{1,1}$ and $\\hat{\\beta}_{1,2}$, together with their standard errors and their correlation following the usual rules for the variance of a linear combination of two random variables.}\n The willingness to pay $\\lambda$  generally lies in a range, so it is common to compute the estimated value of INB for various values of $\\lambda$. In the original study, the reported INB was calculated using  $\\lambda= \\pounds 30000$, which is within the range of cost-effectiveness thresholds used by the UK National Institute for Health and Care Excellence (NICE) \\cite{NICE}.\n\nThe ITT analysis concluded that, compared to medical management, the arm assigned to surgery had a large gain in average QALYs, at a small additional cost and was relatively cost-effective with a positive mean INB, albeit with 95\\% confidence intervals (CI) that included zero (Table \\ref{TableReflux1}).\nThe ITT results cannot however be interpreted as a causal effect of the treatment, since 21\\% of those randomised to surgery, switched and received medical management. An observational study conducted alongside the RCT reported that in routine clinical practice, the corresponding proportion who switched from an intention to have surgery and received medical management, was relatively low (4\\%), with a further 2\\% switching from control to intervention \\cite{Grant2013}. Hence, there is interest in reporting the CACE to give the corresponding treatment effects for those who comply in the RCT. In Section \\ref{Sec:RefluxCACE},  we re-analyse the REFLUX dataset using the methods proposed below, to provide CACEs that recognise the joint distribution of the cost and effectiveness outcomes.\n\n\\section{Complier Average Causal effects with bivariate outcomes}\\label{Sec:CACE}\n\nWe now define more formally our estimands and assumptions. Let ${Y_{1i}}$ and ${Y_{2i}}$ be the continuous bivariate outcomes, and $Z_i$ and $D_i$ the binary the random treatment allocation and treatment received respectively, corresponding to the $i$-th individual. The bivariate endpoints $Y_1$ and $Y_2$ have a common cause, denoted with the latent variable $L$. We assume that there is an unobserved variable $U$ which is associated with the treatment received and either or both of the outcomes, as in Figure \\ref{dag}.\n\nUsing the language of potential outcomes, we denote by $D_i\\left(z_i\\right)$, the potential treatment received by the $i$-th subject  under the  random assignment at level $z_i \\in \\{0, 1\\}$. For example, $D_i(0)$ and $D_i(1)$ denote the potential treatment received if the $i$-th subject were allocated to control,  and treatment respectively.  Similarly, $Y_{\\ell i}\\left(z_i,d_i\\right)$ with $\\ell\\in\\{1,2\\}$ denotes the corresponding potential outcome for endpoint $\\ell$ if the $i$-th subject were allocated to level $z_i$ of the treatment and received level $d_i$. There are four potential outcomes. Since each subject is randomised to one level of treatment, only one of the potential outcomes per endpoint $\\ell$, is observed, {\\textsl{i.e.}\\ } $Y_{\\ell i}=Y_{\\ell i}(Z_i,D_i(Z_i))$\n\n\nThe CACE for outcome $\\ell$ is then defined as \n\\newline$\\theta_{\\ell}=E\\left[\\{Y_{\\ell i}(1,1)-Y_{\\ell i}(0,0)\\}\\big|\\{D_i(1)-D_i(0)=1\\}\\right].$\n\nFor identification of the CACE, the following five assumptions are required \\cite{Angrist1996}: \\vskip 1ex\n\\noindent\\textbf{Stable Unit Treatment Value Assumption (SUTVA)}:\nThe potential outcomes of the $i$-th individual are unrelated to the treatment status of all other individuals and there are no different versions of the treatment that have different effects.\n\\\\ \\textbf{Random Assignment of the treatment $\\mathbf{Z_i}$.} The allocation of treatment $Z_i$ is independent of measured and unmeasured confounders.\n\\\\ \\textbf{The random assignment predicts treatment received}: $Pr\\{D_i(1)=1\\}\\neq Pr\\{D_i(0)=1\\}$\n\\\\  \\textbf{Exclusion restriction}: The effect of $Z$ on $Y_\\ell$ must be via an effect of $Z$ on $D$; $Z$ cannot affect $Y_\\ell$ directly.\n\\\\ \\textbf{Monotonicity:} $Pr\\{D_i(1)\\geq D_i(0)\\}=1$.\n\\\\\n\\begin{figure}[h]\\caption{DAG for a scenario where randomisation $Z$ identifies the causal effects of $D$ on the bivariate outcomes $Y_1$ and $Y_2$, in the presence of the unobserved confounder $U$.}\\label{dag}\n\\begin{center}\n\\includegraphics[scale=1.3]{dag}\n\\end{center}\n\\end{figure}\n\\vskip 2ex\n In Figure \\ref{dag}, $Z$ satisfies the IV assumptions for identification of the CACE. Under these assumptions, the simplest method of estimation in the IV framework is the Wald estimator \\cite{Angrist1996}. For binary instrument, this can be written as :\n", "itemtype": "equation", "pos": 7839, "prevtext": "\n\n\n\n\n\\title{Instrumental variable approaches for estimating complier average causal effects on bivariate outcomes in randomised trials with non-compliance}\n\\date{}\n\\author{K.~DiazOrdaz\\footnote{e-mail: karla.diaz-ordaz@lshtm.ac.uk},  A.~J.~Franchini, R.~Grieve}\n\n\\maketitle\n\n\\subsection*{Abstract}\nIn Randomised Controlled Trials (RCT) with treatment non-compliance, instrumental variable (IV) approaches can be used to estimate complier average causal effects (CACE), by for example, two-stage least squares (2sls). We extend these approaches to multivariate settings, such as cost-effectiveness analyses. We propose a three-stage least squares (3sls) regression approach, which combines 2sls with a seemingly unrelated regression system of equations.  We also consider two `unadjusted' Bayesian models that ignore the correlation between the errors of the treatment received and outcome models, but allow the use of non-normal distributions. Finally, we develop a Bayesian full likelihood approach (BFL), which jointly models the effects of random assignment on treatment received and the outcomes.\n\n\\noindent We investigate the methods' performance in estimating CACE in cost-effectiveness studies with a simulation and a re-analysis of an RCT. We contrast these methods to applying separate 2sls to estimate CACE for each endpoint. Costs are assumed to follow Normal, Gamma or Inverse Gaussian distributions, to have positive or negative correlation with health outcomes, with different levels of non-compliance (30\\% or 70\\%), and sample sizes (n=100 or 1000).\nWith 30\\% non-compliance, each method provides unbiased estimates. However, with high levels of non-compliance, both unadjusted Bayesian methods provide biased estimates. The 2sls approach, while unbiased, reports Confidence Interval (CI) coverage above (positive correlation), and below (negative correlation) nominal levels. By contrast, the BFL and 3sls methods provide estimates with low levels of bias and CI coverage rates which are close to nominal levels throughout.\\\\\n\\textbf{\\textit{keywords:}} non-compliance, instrumental variables, bivariate outcomes, cost-effectiveness.\n\n\n\\section{Introduction}\n\n Non-compliance is a common problem in Randomised Controlled Trials (RCTs), as some participants depart from their randomised treatment, by for example switching from the experimental to the control regimen. An unbiased estimate of the effectiveness of treatment assignment can be obtained by reporting the intention-to-treat (ITT) estimand. In the presence of non-compliance, a complimentary estimand of interest is the causal effect of treatment received. Instrumental variable (IV) methods can be used to obtain the complier average causal effect (CACE), as long as random assignment meets the IV criteria for identification \\cite{Angrist1996}. An established approach to IV estimation is two-stage least squares (2sls), which provides consistent estimates of the CACE when the outcome measure is continuous, and non-compliance is binary \\cite{Baiocchi2014}.\n\n\nCost-effectiveness analyses (CEA) are an important source of evidence for informing clinical decision-making and health policy. CEA commonly report an ITT estimand, {\\textsl{i.e.}\\ } the relative cost-effectiveness of the intention to receive the intervention \\cite{NICE}. However, policy-makers may require additional estimands, such as the relative cost-effectiveness for compliers. For example, CEAs of new therapies for end-stage cancer, are required to estimate the cost-effectiveness of treatment receipt, recognising that patients may switch from their randomised allocation following disease progression. Alternative estimands such as the CACE may also be  useful when levels of non-compliance in the RCT are not representative of the expected levels in the population of interest, and in situations where the relative costs depend on receipt of the intervention, rather than on the intention to receive either treatment or control.\nMethods for obtaining the CACE for univariate survival outcomes have been exemplified before \\cite{Latimer2014}, but approaches for addressing non-compliance in CEA more generally, have received little attention \\cite{Brilleman2015}. The CEA  context highlights an important complexity that arises with multivariate outcomes more widely, in that, to provide accurate measures of the uncertainty surrounding a composite measure of interest, for example the incremental net monetary benefit (INB), it is necessary to recognise the correlation between the endpoints, in this case, cost and health outcomes \\cite{Willan2003,Willan2006a}.  Indeed, when faced with non-compliance, and the requirement to estimate a casual effect of treatment on cost-effectiveness endpoints, some CEA resort to per protocol (PP) analyses \\cite{Brilleman2015}, which exclude participants who deviate from treatment. As non-compliance is likely to be associated with prognostic variables, only some of which are observed, PP analyses are liable to provide biased estimates of the causal effect of the treatment received.\n\nHere, we propose alternative methods for estimating CACE in RCTs with non-compliance and multivariate outcomes. The first approach is an extension of 2sls, known as three stage least squares (3sls) \\cite{Zellner1963}, which allows the estimation of  a system of simultaneous equations with endogenous regressors. Next, we consider a bivariate version of the `unadjusted Bayesian' models previously proposed for Mendelian randomisation \\cite{Burgess2012}, which simultaneously estimate the expected treatment received as a function of random allocation, and the mean outcomes as a linear function of the expected treatment received. Finally, we develop a Bayesian full likelihood approach (BFL), whereby the outcome variables and the treatment received are jointly modelled as dependent on the random assignment. This is an extension to the multivariate case of what is known in the econometrics literature as the IV unrestricted reduced form \\cite{Kleibergen2003}.\n\nThe aim of this paper is to present and compare these alternative approaches. The problem is illustrated in Section \\ref{Sec:Reflux} with the REFLUX study, a multicentre RCT and CEA that contrasts laparoscopic surgery with medical management for patients with Gastro-Oesophageal Reflux Disease (GORD). Section \\ref{Sec:CACE} introduces the assumptions and methods for estimating CACEs. In Section \\ref{Sec:sim}, we assess the performance of the alternative approaches in a simulation study and the case study (Section \\ref{Sec:RefluxCACE}). We conclude with a Discussion (Section \\ref{Sec:Discussion}), where we consider the findings from this study in the context of related research.\n\n\n\\section{Motivating example: Cost-effectiveness analysis of the REFLUX study}\\label{Sec:Reflux}\nThe REFLUX study was a UK multicentre RCT with a parallel design, in which patients with moderately severe GORD, were randomly assigned to medical management or laparoscopic surgery  \\cite{Grant2008, Grant2008a, Grant2013}. Individual resource use (cost) and health-related quality of life data (EQ-5D) were collected annually. Total Quality-Adjusted Life Years (QALYs)  and costs per patient were reported over the RCT follow-up period of five years. As is typical, the costs were right-skewed. Table \\ref{TableReflux1} reports the main characteristics of this case study.\n\n The original CEA estimated the linear additive treatment effect on mean costs and health outcomes (QALYs) on complete cases ($n=172$, representing 48\\% of the total sample size). The primary analysis used a system of seemingly unrelated regression equations (SURs) \\cite{Zellner1962, Willan2004}, with no covariate adjustment.\n\nBriefly, the SURs can be written for our bivariate outcomes, cost $Y_{1i}$ and QALYs $Y_{2i}$, as follows\n\n", "index": 1, "text": "\\begin{equation}\\label{sur}\n\\begin{array}{c}\nY_{1i} = \\beta_{0,1}+ \\beta_{1,1} \\mbox{treat}_i + \\epsilon_{1i}\\\\\nY_{2i}= \\beta_{0,2}+\\beta_{1,2} \\mbox{treat}_i + \\epsilon_{2i}\n\\end{array}\\ \\ \\ \\ \\ \\ \\ \\ \\begin{array}{c}\n\\left(\\begin{array}{c}\n\\epsilon_{1i}\\\\ \\epsilon_{2i}\\end{array}\\right)\\sim\n\\mathcal{F}(0,\\Sigma)\n\\end{array}\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E1.m1\" class=\"ltx_Math\" alttext=\"\\begin{array}[]{c}Y_{1i}=\\beta_{0,1}+\\beta_{1,1}\\mbox{treat}_{i}+\\epsilon_{1i}%&#10;\\\\&#10;Y_{2i}=\\beta_{0,2}+\\beta_{1,2}\\mbox{treat}_{i}+\\epsilon_{2i}\\end{array}\\ \\ \\ %&#10;\\ \\ \\ \\ \\ \\begin{array}[]{c}\\left(\\begin{array}[]{c}\\epsilon_{1i}\\\\&#10;\\epsilon_{2i}\\end{array}\\right)\\sim\\mathcal{F}(0,\\Sigma)\\end{array}\" display=\"block\"><mrow><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"center\"><mrow><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>\u2062</mo><msub><mtext>treat</mtext><mi>i</mi></msub></mrow><mo>+</mo><msub><mi>\u03f5</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mrow></mrow></mtd></mtr><mtr><mtd columnalign=\"center\"><mrow><msub><mi>Y</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>\u2062</mo><msub><mtext>treat</mtext><mi>i</mi></msub></mrow><mo>+</mo><msub><mi>\u03f5</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mrow></mrow></mtd></mtr></mtable><mo mathvariant=\"italic\" separator=\"true\">\u2003\u2003\u2003\u2003</mo><mtable displaystyle=\"true\"><mtr><mtd columnalign=\"center\"><mrow><mrow><mo>(</mo><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"center\"><msub><mi>\u03f5</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>\u03f5</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr></mtable><mo>)</mo></mrow><mo>\u223c</mo><mrow><mi class=\"ltx_font_mathcaligraphic\">\u2131</mi><mo>\u2062</mo><mrow><mo stretchy=\"false\">(</mo><mn>0</mn><mo>,</mo><mi mathvariant=\"normal\">\u03a3</mi><mo stretchy=\"false\">)</mo></mrow></mrow></mrow></mtd></mtr></mtable></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\n\nTypically, estimation of these conditional expectations proceeds via an approach known as two-stage least squares (2sls). The first stage fits a linear regression to treatment received on treatment assigned. Then, in a second stage,  a regression model of outcome on predicted treatment received is fitted:\n\\begin{eqnarray}\\label{2sls}\n\\nonumber D_i &= &\\alpha_0 + \\alpha_1Z_i + \\omega_{1i}\\\\\nY_{\\ell i} &=& \\beta_0 + \\beta_{IV} \\hat{D_i} + \\omega_{2i}\n\\end{eqnarray}\n\\noindent In this second stage regression model, $\\hat{\\beta}_{IV} $ is an estimator for $\\theta_{\\ell}$.\n\nNote that the first-stage model needs to be a linear model, even when the treatment received is binary. This is because only OLS estimation is guaranteed to produce first-stage residuals $\\omega_{1i}$ that are uncorrelated with the predicted values for $D$ \\cite{AngristBook}.\nTo obtain the correct standard errors for the 2sls estimator, it is necessary to take into account the uncertainty about the first stage estimates.\n\nA key issue for settings such as CEA where there is interest in estimating the CACE for bivariate outcomes, is that 2sls can only be applied to estimate causal effects for univariate outcomes, ignoring the correlation between the different endpoints. This is a concern for reporting recommended statistics such as the confidence interval (CI) around a function of the outcomes, like the INB in CEA, which requires accurate estimates of the covariance between the outcomes of interest (e.g. costs and QALYs).\nA simple way to address this problem would be to apply 2sls directly to the composite measure.\nHowever if the function of interest is a one-parameter family, as in the case of the INB, then this solution becomes impractical, as to provide the policy-maker with the requisite estimates of the INB for different values of $\\lambda$, would require a series of separate 2sls regressions. Moreover, if the composite measure is not a linear function of the outcomes, then this approach would not be valid.  Therefore, we present three more flexible strategies for estimating the CACE of multivariate outcomes. The first approach combines SURs (equation \\ref{sur}) and 2sls (equation \\ref{2sls}) to obtain CACEs for both outcomes accounting for their correlation. This is known in the econometrics literature as three-stage least squares (3sls).\n\n\\subsection{Three-stage least squares}\nThree-stage least squares (3sls) was developed for SUR systems with {\\it endogenous} regressors, {\\textsl{i.e.}\\ } any explanatory variables which are correlated with the error term in equations \\eqref{sur} \\cite{Zellner1963}. All the parameters appearing in the system are estimated jointly, in three stages. The first two stages are as for 2sls, but with the second stage applied to each of the outcomes.\n\\begin{eqnarray}\\label{3sls}\n\\nonumber\\mbox{(1st stage):}\\qquad D_i &=& \\alpha_0 + \\alpha_1Z_i + e_{0i}\\\\\n\\mbox{(2nd stage):}\\qquad Y_{1i} &=& \\beta_{01} + \\beta_{IV,1} \\hat{D_i} + e_{1i} \\\\\n\\label{3sls2}Y_{2i} &=& \\beta_{02} + \\beta_{IV,2} \\hat{D_i} + e_{2i}\n\\end{eqnarray}\n\nThe third stage is the same step used on a SUR with exogenous regressors (equation \\eqref{sur}) for estimating the covariance matrix of the error terms from the two equations \\eqref{3sls} and \\eqref{3sls2}. Thus, in keeping with the identification assumptions required for the CACE (and made by 2sls), the first stage residuals $e_{0i}$ are uncorrelated with the residuals from the second-stage equations, here $e_{1i}$ and $e_{2i}$.  The extension to 2sls is that, 3sls obtains the covariance matrix between the residuals $e_{1i}$ and $e_{2i}$.\n\nFor estimation, we use  feasible generalised least squares (FGLS).  We note that the 3sls estimator based on FGLS is consistent only if the error terms in each equation of the system and the instrument are independent. It does not make any distributional assumptions and is robust to heteroscedasticity of the errors in the linear models for the outcomes \\cite{Greene2002}. In settings where this condition is not satisfied, other estimation approaches such as generalised methods of moments (GMM) warrant consideration   \\cite{Schmidt1990}. In the just-identified case, {\\textsl{i.e.}\\ } when there are as many endogenous regressors as there are instruments,  as is the case here,  classical theory about 3sls estimators shows that the GMM and the FGLS estimators coincide \\cite{Greene2002}. Because the 3sls method uses an estimated variance-covariance matrix, it is only asymptotically efficient \\cite{Greene2002}.\n\n\\subsection{Unadjusted Bayesian estimators}\n\n  Bayesian models have a natural appeal for multivariate outcome analyses, for example CEA, because they allows us to model the outcomes jointly, and  offer a wide range of different distributions. This can provide more efficient estimates of incremental costs and cost-effectiveness, given the notoriously right-skewed nature of cost data \\cite{Nixon2005}.\n\nFor simplicity of exposition, we begin by assuming normality for both outcomes. We have a marginal model for $Y_1$ \\cite{Nixon2005}\n\n", "itemtype": "equation", "pos": 13373, "prevtext": "\nwhere $\\beta_{1,1}$ and $\\beta_{1,2}$ represent the incremental costs and QALYs respectively.  The distribution of the errors $\\mathcal{F}$ is not assumed to be normal.\n\nIn addition to reporting incremental costs and  QALYs, CEA often report the INB, defined as\n$\\mbox{INB}(\\lambda) = \\lambda \\beta_{1,2}-\\beta_{1,1}$, where  $\\lambda$ represents the decision-makers {\\it willingness to pay} for a one unit gain in health outcome. Thus the new treatment is cost-effective if $\\mbox{INB}>0$. \\footnote{For a given $\\lambda$, the standard error of INB can be estimated from the estimated increments $\\hat{\\beta}_{1,1}$ and $\\hat{\\beta}_{1,2}$, together with their standard errors and their correlation following the usual rules for the variance of a linear combination of two random variables.}\n The willingness to pay $\\lambda$  generally lies in a range, so it is common to compute the estimated value of INB for various values of $\\lambda$. In the original study, the reported INB was calculated using  $\\lambda= \\pounds 30000$, which is within the range of cost-effectiveness thresholds used by the UK National Institute for Health and Care Excellence (NICE) \\cite{NICE}.\n\nThe ITT analysis concluded that, compared to medical management, the arm assigned to surgery had a large gain in average QALYs, at a small additional cost and was relatively cost-effective with a positive mean INB, albeit with 95\\% confidence intervals (CI) that included zero (Table \\ref{TableReflux1}).\nThe ITT results cannot however be interpreted as a causal effect of the treatment, since 21\\% of those randomised to surgery, switched and received medical management. An observational study conducted alongside the RCT reported that in routine clinical practice, the corresponding proportion who switched from an intention to have surgery and received medical management, was relatively low (4\\%), with a further 2\\% switching from control to intervention \\cite{Grant2013}. Hence, there is interest in reporting the CACE to give the corresponding treatment effects for those who comply in the RCT. In Section \\ref{Sec:RefluxCACE},  we re-analyse the REFLUX dataset using the methods proposed below, to provide CACEs that recognise the joint distribution of the cost and effectiveness outcomes.\n\n\\section{Complier Average Causal effects with bivariate outcomes}\\label{Sec:CACE}\n\nWe now define more formally our estimands and assumptions. Let ${Y_{1i}}$ and ${Y_{2i}}$ be the continuous bivariate outcomes, and $Z_i$ and $D_i$ the binary the random treatment allocation and treatment received respectively, corresponding to the $i$-th individual. The bivariate endpoints $Y_1$ and $Y_2$ have a common cause, denoted with the latent variable $L$. We assume that there is an unobserved variable $U$ which is associated with the treatment received and either or both of the outcomes, as in Figure \\ref{dag}.\n\nUsing the language of potential outcomes, we denote by $D_i\\left(z_i\\right)$, the potential treatment received by the $i$-th subject  under the  random assignment at level $z_i \\in \\{0, 1\\}$. For example, $D_i(0)$ and $D_i(1)$ denote the potential treatment received if the $i$-th subject were allocated to control,  and treatment respectively.  Similarly, $Y_{\\ell i}\\left(z_i,d_i\\right)$ with $\\ell\\in\\{1,2\\}$ denotes the corresponding potential outcome for endpoint $\\ell$ if the $i$-th subject were allocated to level $z_i$ of the treatment and received level $d_i$. There are four potential outcomes. Since each subject is randomised to one level of treatment, only one of the potential outcomes per endpoint $\\ell$, is observed, {\\textsl{i.e.}\\ } $Y_{\\ell i}=Y_{\\ell i}(Z_i,D_i(Z_i))$\n\n\nThe CACE for outcome $\\ell$ is then defined as \n\\newline$\\theta_{\\ell}=E\\left[\\{Y_{\\ell i}(1,1)-Y_{\\ell i}(0,0)\\}\\big|\\{D_i(1)-D_i(0)=1\\}\\right].$\n\nFor identification of the CACE, the following five assumptions are required \\cite{Angrist1996}: \\vskip 1ex\n\\noindent\\textbf{Stable Unit Treatment Value Assumption (SUTVA)}:\nThe potential outcomes of the $i$-th individual are unrelated to the treatment status of all other individuals and there are no different versions of the treatment that have different effects.\n\\\\ \\textbf{Random Assignment of the treatment $\\mathbf{Z_i}$.} The allocation of treatment $Z_i$ is independent of measured and unmeasured confounders.\n\\\\ \\textbf{The random assignment predicts treatment received}: $Pr\\{D_i(1)=1\\}\\neq Pr\\{D_i(0)=1\\}$\n\\\\  \\textbf{Exclusion restriction}: The effect of $Z$ on $Y_\\ell$ must be via an effect of $Z$ on $D$; $Z$ cannot affect $Y_\\ell$ directly.\n\\\\ \\textbf{Monotonicity:} $Pr\\{D_i(1)\\geq D_i(0)\\}=1$.\n\\\\\n\\begin{figure}[h]\\caption{DAG for a scenario where randomisation $Z$ identifies the causal effects of $D$ on the bivariate outcomes $Y_1$ and $Y_2$, in the presence of the unobserved confounder $U$.}\\label{dag}\n\\begin{center}\n\\includegraphics[scale=1.3]{dag}\n\\end{center}\n\\end{figure}\n\\vskip 2ex\n In Figure \\ref{dag}, $Z$ satisfies the IV assumptions for identification of the CACE. Under these assumptions, the simplest method of estimation in the IV framework is the Wald estimator \\cite{Angrist1996}. For binary instrument, this can be written as :\n", "index": 3, "text": "\n\\[\n\\hat{\\theta}_{\\ell, IV} = \\frac{E(Y|Z=1) - E(Y|Z=0)}{E(D|Z=1) - E(D|Z=0)}\n\\]\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.Ex1.m1\" class=\"ltx_Math\" alttext=\"\\hat{\\theta}_{\\ell,IV}=\\frac{E(Y|Z=1)-E(Y|Z=0)}{E(D|Z=1)-E(D|Z=0)}\" display=\"block\"><mrow><msub><mover accent=\"true\"><mi>\u03b8</mi><mo stretchy=\"false\">^</mo></mover><mrow><mi mathvariant=\"normal\">\u2113</mi><mo>,</mo><mrow><mi>I</mi><mo>\u2062</mo><mi>V</mi></mrow></mrow></msub><mo>=</mo><mfrac><mrow><mi>E</mi><mrow><mo stretchy=\"false\">(</mo><mi>Y</mi><mo stretchy=\"false\">|</mo><mi>Z</mi><mo>=</mo><mn>1</mn><mo stretchy=\"false\">)</mo></mrow><mo>-</mo><mi>E</mi><mrow><mo stretchy=\"false\">(</mo><mi>Y</mi><mo stretchy=\"false\">|</mo><mi>Z</mi><mo>=</mo><mn>0</mn><mo stretchy=\"false\">)</mo></mrow></mrow><mrow><mi>E</mi><mrow><mo stretchy=\"false\">(</mo><mi>D</mi><mo stretchy=\"false\">|</mo><mi>Z</mi><mo>=</mo><mn>1</mn><mo stretchy=\"false\">)</mo></mrow><mo>-</mo><mi>E</mi><mrow><mo stretchy=\"false\">(</mo><mi>D</mi><mo stretchy=\"false\">|</mo><mi>Z</mi><mo>=</mo><mn>0</mn><mo stretchy=\"false\">)</mo></mrow></mrow></mfrac></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\nand then, we write a model for $Y_2$  conditional on $Y_1$\n\n", "itemtype": "equation", "pos": 18528, "prevtext": "\n\nTypically, estimation of these conditional expectations proceeds via an approach known as two-stage least squares (2sls). The first stage fits a linear regression to treatment received on treatment assigned. Then, in a second stage,  a regression model of outcome on predicted treatment received is fitted:\n\\begin{eqnarray}\\label{2sls}\n\\nonumber D_i &= &\\alpha_0 + \\alpha_1Z_i + \\omega_{1i}\\\\\nY_{\\ell i} &=& \\beta_0 + \\beta_{IV} \\hat{D_i} + \\omega_{2i}\n\\end{eqnarray}\n\\noindent In this second stage regression model, $\\hat{\\beta}_{IV} $ is an estimator for $\\theta_{\\ell}$.\n\nNote that the first-stage model needs to be a linear model, even when the treatment received is binary. This is because only OLS estimation is guaranteed to produce first-stage residuals $\\omega_{1i}$ that are uncorrelated with the predicted values for $D$ \\cite{AngristBook}.\nTo obtain the correct standard errors for the 2sls estimator, it is necessary to take into account the uncertainty about the first stage estimates.\n\nA key issue for settings such as CEA where there is interest in estimating the CACE for bivariate outcomes, is that 2sls can only be applied to estimate causal effects for univariate outcomes, ignoring the correlation between the different endpoints. This is a concern for reporting recommended statistics such as the confidence interval (CI) around a function of the outcomes, like the INB in CEA, which requires accurate estimates of the covariance between the outcomes of interest (e.g. costs and QALYs).\nA simple way to address this problem would be to apply 2sls directly to the composite measure.\nHowever if the function of interest is a one-parameter family, as in the case of the INB, then this solution becomes impractical, as to provide the policy-maker with the requisite estimates of the INB for different values of $\\lambda$, would require a series of separate 2sls regressions. Moreover, if the composite measure is not a linear function of the outcomes, then this approach would not be valid.  Therefore, we present three more flexible strategies for estimating the CACE of multivariate outcomes. The first approach combines SURs (equation \\ref{sur}) and 2sls (equation \\ref{2sls}) to obtain CACEs for both outcomes accounting for their correlation. This is known in the econometrics literature as three-stage least squares (3sls).\n\n\\subsection{Three-stage least squares}\nThree-stage least squares (3sls) was developed for SUR systems with {\\it endogenous} regressors, {\\textsl{i.e.}\\ } any explanatory variables which are correlated with the error term in equations \\eqref{sur} \\cite{Zellner1963}. All the parameters appearing in the system are estimated jointly, in three stages. The first two stages are as for 2sls, but with the second stage applied to each of the outcomes.\n\\begin{eqnarray}\\label{3sls}\n\\nonumber\\mbox{(1st stage):}\\qquad D_i &=& \\alpha_0 + \\alpha_1Z_i + e_{0i}\\\\\n\\mbox{(2nd stage):}\\qquad Y_{1i} &=& \\beta_{01} + \\beta_{IV,1} \\hat{D_i} + e_{1i} \\\\\n\\label{3sls2}Y_{2i} &=& \\beta_{02} + \\beta_{IV,2} \\hat{D_i} + e_{2i}\n\\end{eqnarray}\n\nThe third stage is the same step used on a SUR with exogenous regressors (equation \\eqref{sur}) for estimating the covariance matrix of the error terms from the two equations \\eqref{3sls} and \\eqref{3sls2}. Thus, in keeping with the identification assumptions required for the CACE (and made by 2sls), the first stage residuals $e_{0i}$ are uncorrelated with the residuals from the second-stage equations, here $e_{1i}$ and $e_{2i}$.  The extension to 2sls is that, 3sls obtains the covariance matrix between the residuals $e_{1i}$ and $e_{2i}$.\n\nFor estimation, we use  feasible generalised least squares (FGLS).  We note that the 3sls estimator based on FGLS is consistent only if the error terms in each equation of the system and the instrument are independent. It does not make any distributional assumptions and is robust to heteroscedasticity of the errors in the linear models for the outcomes \\cite{Greene2002}. In settings where this condition is not satisfied, other estimation approaches such as generalised methods of moments (GMM) warrant consideration   \\cite{Schmidt1990}. In the just-identified case, {\\textsl{i.e.}\\ } when there are as many endogenous regressors as there are instruments,  as is the case here,  classical theory about 3sls estimators shows that the GMM and the FGLS estimators coincide \\cite{Greene2002}. Because the 3sls method uses an estimated variance-covariance matrix, it is only asymptotically efficient \\cite{Greene2002}.\n\n\\subsection{Unadjusted Bayesian estimators}\n\n  Bayesian models have a natural appeal for multivariate outcome analyses, for example CEA, because they allows us to model the outcomes jointly, and  offer a wide range of different distributions. This can provide more efficient estimates of incremental costs and cost-effectiveness, given the notoriously right-skewed nature of cost data \\cite{Nixon2005}.\n\nFor simplicity of exposition, we begin by assuming normality for both outcomes. We have a marginal model for $Y_1$ \\cite{Nixon2005}\n\n", "index": 5, "text": "\\begin{equation}\\label{eq:cost}\n Y_{1i}\\sim N(\\mu_{1i}, {\\sigma^2}_1)\\qquad \\mu_{1i} = \\beta_{0,1}+ \\beta_{1,1} \\mbox{treat}_i\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E2.m1\" class=\"ltx_Math\" alttext=\"Y_{1i}\\sim N(\\mu_{1i},{\\sigma^{2}}_{1})\\qquad\\mu_{1i}=\\beta_{0,1}+\\beta_{1,1}%&#10;\\mbox{treat}_{i}\" display=\"block\"><mrow><mrow><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>\u223c</mo><mrow><mi>N</mi><mo>\u2062</mo><mrow><mo stretchy=\"false\">(</mo><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>,</mo><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>1</mn><none/></mmultiscripts><mo stretchy=\"false\">)</mo></mrow></mrow></mrow><mo mathvariant=\"italic\" separator=\"true\">\u2003\u2003</mo><mrow><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>\u2062</mo><msub><mtext>treat</mtext><mi>i</mi></msub></mrow></mrow></mrow></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\nwhere $\\rho$ is the correlation between the outcomes.  The linear relationship between the two outcomes is represented by $\\beta_{2,2}=\\rho\\frac{ \\sigma_2}{\\sigma_1}$.\n\nBecause of the non-compliance, in order to obtain a causal estimate of treatment, we need to add a linear model for the treatment received, dependent on randomisation $Z_i$. Formally,  this model (denoted uBN, for unadjusted Bayesian Normal) can be written with three equations as follows:\n\n", "itemtype": "equation", "pos": 18729, "prevtext": "\nand then, we write a model for $Y_2$  conditional on $Y_1$\n\n", "index": 7, "text": "\\begin{equation}\\label{eq:qaly}\n Y_{2i}\\mid Y_{1i}\\sim N(\\mu_{2i}, {\\sigma^2}_2(1-\\rho^2)) \\qquad\n\\mbox{E}\\mu_{2i}= \\beta_{0,2}+\\beta_{1,2}\\mbox{treat}_i+ \\beta_{2,2} (y_{1i}-\\mu_{1i}),\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E3.m1\" class=\"ltx_Math\" alttext=\"Y_{2i}\\mid Y_{1i}\\sim N(\\mu_{2i},{\\sigma^{2}}_{2}(1-\\rho^{2}))\\qquad\\mbox{E}%&#10;\\mu_{2i}=\\beta_{0,2}+\\beta_{1,2}\\mbox{treat}_{i}+\\beta_{2,2}(y_{1i}-\\mu_{1i}),\" display=\"block\"><mrow><msub><mi>Y</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>\u2223</mo><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>\u223c</mo><mi>N</mi><mrow><mo stretchy=\"false\">(</mo><msub><mi>\u03bc</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>,</mo><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>2</mn><none/></mmultiscripts><mrow><mo stretchy=\"false\">(</mo><mn>1</mn><mo>-</mo><msup><mi>\u03c1</mi><mn>2</mn></msup><mo stretchy=\"false\">)</mo></mrow><mo stretchy=\"false\">)</mo></mrow><mo mathvariant=\"italic\" separator=\"true\">\u2003\u2003</mo><mtext>E</mtext><msub><mi>\u03bc</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>+</mo><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>2</mn></mrow></msub><msub><mtext>treat</mtext><mi>i</mi></msub><mo>+</mo><msub><mi>\u03b2</mi><mrow><mn>2</mn><mo>,</mo><mn>2</mn></mrow></msub><mrow><mo stretchy=\"false\">(</mo><msub><mi>y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>-</mo><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo stretchy=\"false\">)</mo></mrow><mo>,</mo></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\n This model is a bivariate version of the `unadjusted Bayesian' method previously proposed for Mendelian randomisation \\cite{Burgess2012}. The causal treatment effect for outcome $Y_\\ell$, with $\\ell\\in\\{1,2\\}$, is represented by  $\\beta_{1,\\ell}$ in equations \\eqref{uBN}.\n\nFor the implementation, we express  $\\beta_{2,2}= \\rho\\frac{ \\sigma_2 }{\\sigma_1}$, and assume a vague normal prior $N(0, 10^2)$ on the Fisher's z-transform of $\\rho$. We also use vague normal priors for each regression coefficient  {\\textsl{i.e.}\\ } $\\beta_{m,j}\\sim N(0, 10^2)$, for $j \\in\\{0,1,2\\}, m\\in\\{0,1\\}$. For standard deviations, we use $\\sigma_j\\sim\\mbox{Unif}(0,10)$, for $j \\in\\{0,1,2\\}$.\n\n\nNext, we relax the normality assumption of equation \\eqref{uBN}, by modelling $Y_1$ ({\\textsl{i.e.}\\ } cost) with a Gamma distribution, and treatment received (binary), with a logistic regression. The health outcomes, $Y_2$, are still modelled with a normal distribution, as is customary. Because we are using a non-linear model for the treatment received, we use the predicted raw residuals from this model as extra regressors in the outcome models, similar to the 2-stage residual inclusion estimator \\cite{Terza2008}. We model  $Y_1$ by its marginal distribution (Gamma) and  $Y_2$ by a conditional Normal distribution, given $Y_1$ \\cite{Nixon2005}. We call this model `unadjusted Bayesian Gamma-Normal' (uBGN)  and write it as follows\n\\begin{eqnarray}\\label{equBGN}\n\\begin{array}{l}\n\\nonumber D_i \\sim \\mbox{Bern}(\\pi_{i}) \\\\\n\\nonumber Y_{1i}\\sim \\mbox{Gamma}(\\nu_{1i}, \\kappa_1)\\\\\nY_{2i}\\mid Y_{1i}\\sim N(\\mu_{2i}, {\\sigma^2}_2(1-\\rho^2)) \\\\\n\\end{array}\\ \\ \\ \\ \\ \\ \\ \\\n\\begin{array}{l}\n\\nonumber {\\text{logit}}(\\pi_{i})  = \\alpha_0 + \\alpha_1Z_i \\\\\n\\nonumber r_{i} = D_i-\\pi_i \\\\\n\\nonumber\\mu_{1i}= \\beta_{0,1}+ \\beta_{1,1} D_{i}+ \\beta_{1,r} r_{i} \\\\\n\\mu_{2i}= \\beta_{0,2}+\\beta_{1,2}D_{i}+ \\beta_{2,r} r_{i} +\\beta_{2,2} (y_{1i}-\\mu_{1i})\n\\end{array}\n\\end{eqnarray}\nwhere $\\mu_{1}=\\frac{\\nu_1}{\\kappa_1}$, is the mean of the Gamma distributed costs, with shape $\\nu_1$ and rate $\\kappa_1$.\n\nThe prior distribution for $\\nu_1$ is $\\mbox{Gamma}(0.01, 0.01)$. We also assume a Gamma prior for the intercept term of the cost equation, $\\beta_{0,1}\\sim\\mbox{Gamma}(0.01, 0.01)$.  All the other regression parameters have the same priors as those used in the uBN model.\n\n\nThe models introduced in this section, uBN and uBGN, are estimated in one stage, allowing feedback between the regression equations and the propagation of uncertainty.  However, these 'unadjusted' methods assume that the outcomes and the treatment received are independent, conditional on treatment allocation. The resulting bias in the causal estimate  $\\beta_{1,\\ell}$ is likely to be more important at higher levels of non-compliance.\n\n\\subsection{Bayesian IV with simultaneous equations (BFL)}\n\nWe now introduce an approach that models the covariance between treatment received and outcomes explicitly, using a  system of simultaneous equations. This can be done via full or limited information maximum likelihood, or by using MCMC to estimate the parameters in the model simultaneously allowing for proper Bayesian feedback and propagation of uncertainty. Here, we follow the Bayesian approach, assuming the endogenous variable  and the outcomes are all covariant and depend on the instrument.\nThis method is an extension of the `adjusted' Bayesian method presented in \\cite{Burgess2012}, equivalent to the expression for the IV unrestricted reduced form in \\cite{Kleibergen2003} and \\cite{Lancaster2004}.\n\nLet $(D_{i}, Y_{1i}, Y_{2i})^\\top$ be the transpose of vector of outcomes, which now includes treatment received, as well as the bivariate endpoints of interest.\nWe treat all three variables as multivariate normally distributed, so that\n \n", "itemtype": "equation", "pos": 19389, "prevtext": "\nwhere $\\rho$ is the correlation between the outcomes.  The linear relationship between the two outcomes is represented by $\\beta_{2,2}=\\rho\\frac{ \\sigma_2}{\\sigma_1}$.\n\nBecause of the non-compliance, in order to obtain a causal estimate of treatment, we need to add a linear model for the treatment received, dependent on randomisation $Z_i$. Formally,  this model (denoted uBN, for unadjusted Bayesian Normal) can be written with three equations as follows:\n\n", "index": 9, "text": "\\begin{equation}\\label{uBN}\n\\begin{array}{l}\nD_{i} \\sim N(\\mu_{0i}, {\\sigma^2}_0) \\\\\n Y_{1i}\\sim N(\\mu_{1i}, {\\sigma^2}_1)\\\\\n Y_{2i}\\big| Y_{1i}\\sim N(\\mu_{2i}, {\\sigma^2}_2(1-\\rho^2)) \\\\\n\\end{array}\\ \\ \\ \\ \\ \\ \\ \\\n\\begin{array}{l}\n\\mu_{0i} = \\beta_{0,0} + \\beta_{1,0}Z_i \\\\\n\\mu_{1i} = \\beta_{0,1}+ \\beta_{1,1} \\mu_{0i}  \\\\\n\\mu_{2i} =  \\beta_{0,2}+\\beta_{1,2} \\mu_{0i}+ \\beta_{2,2} (y_{1i}-\\mu_{1i})\n\\end{array}\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E4.m1\" class=\"ltx_Math\" alttext=\"\\begin{array}[]{l}D_{i}\\sim N(\\mu_{0i},{\\sigma^{2}}_{0})\\\\&#10;Y_{1i}\\sim N(\\mu_{1i},{\\sigma^{2}}_{1})\\\\&#10;Y_{2i}\\big{|}Y_{1i}\\sim N(\\mu_{2i},{\\sigma^{2}}_{2}(1-\\rho^{2}))\\\\&#10;\\end{array}\\ \\ \\ \\ \\ \\ \\ \\ \\begin{array}[]{l}\\mu_{0i}=\\beta_{0,0}+\\beta_{1,0}Z%&#10;_{i}\\\\&#10;\\mu_{1i}=\\beta_{0,1}+\\beta_{1,1}\\mu_{0i}\\\\&#10;\\mu_{2i}=\\beta_{0,2}+\\beta_{1,2}\\mu_{0i}+\\beta_{2,2}(y_{1i}-\\mu_{1i})\\end{array}\" display=\"block\"><mrow><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"left\"><mrow><msub><mi>D</mi><mi>i</mi></msub><mo>\u223c</mo><mrow><mi>N</mi><mo>\u2062</mo><mrow><mo stretchy=\"false\">(</mo><msub><mi>\u03bc</mi><mrow><mn>0</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>,</mo><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>0</mn><none/></mmultiscripts><mo stretchy=\"false\">)</mo></mrow></mrow></mrow></mtd></mtr><mtr><mtd columnalign=\"left\"><mrow><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>\u223c</mo><mrow><mi>N</mi><mo>\u2062</mo><mrow><mo stretchy=\"false\">(</mo><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>,</mo><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>1</mn><none/></mmultiscripts><mo stretchy=\"false\">)</mo></mrow></mrow></mrow></mtd></mtr><mtr><mtd columnalign=\"left\"><mrow><msub><mi>Y</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo maxsize=\"120%\" minsize=\"120%\">|</mo><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>\u223c</mo><mi>N</mi><mrow><mo stretchy=\"false\">(</mo><msub><mi>\u03bc</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>,</mo><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>2</mn><none/></mmultiscripts><mrow><mo stretchy=\"false\">(</mo><mn>1</mn><mo>-</mo><msup><mi>\u03c1</mi><mn>2</mn></msup><mo stretchy=\"false\">)</mo></mrow><mo stretchy=\"false\">)</mo></mrow></mrow></mtd></mtr></mtable><mo mathvariant=\"italic\" separator=\"true\">\u2003\u2003\u2003\u2003</mo><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"left\"><mrow><msub><mi>\u03bc</mi><mrow><mn>0</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>0</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>0</mn></mrow></msub><mo>\u2062</mo><msub><mi>Z</mi><mi>i</mi></msub></mrow></mrow></mrow></mtd></mtr><mtr><mtd columnalign=\"left\"><mrow><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>1</mn></mrow></msub><mo>\u2062</mo><msub><mi>\u03bc</mi><mrow><mn>0</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mrow></mrow></mrow></mtd></mtr><mtr><mtd columnalign=\"left\"><mrow><msub><mi>\u03bc</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>=</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>0</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>1</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>\u2062</mo><msub><mi>\u03bc</mi><mrow><mn>0</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mrow><mo>+</mo><mrow><msub><mi>\u03b2</mi><mrow><mn>2</mn><mo>,</mo><mn>2</mn></mrow></msub><mo>\u2062</mo><mrow><mo stretchy=\"false\">(</mo><mrow><msub><mi>y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub><mo>-</mo><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mrow><mo stretchy=\"false\">)</mo></mrow></mrow></mrow></mrow></mtd></mtr></mtable></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\nwhere $s_{ij}=\\mbox{cov}(Y_i,Y_j)$, and\n\\begin{eqnarray}\\label{MVN_IVBayes}\n\\nonumber\\mu_{0i} &=& \\beta_{0,0} + \\beta_{1,0}Z_i \\\\\n\\nonumber\\mu_{1i} &=& \\beta_{0,1}+ \\beta_{1,1} \\beta_{1,0}Z_i  \\\\\n\\mu_{2i}&=&  \\beta_{0,2}+\\beta_{1,2}\\beta_{1,0}Z_i\n\\end{eqnarray}\nThe causal treatment effect estimates are $\\beta_{1,1}$ and $\\beta_{1,2}$ respectively.  For the implementation, we use vague normal priors for the regression coefficients, {\\textsl{i.e.}\\ } $\\beta_{m,j}\\sim N(0, 10^2)$, for $j \\in\\{0,1,2\\}, m\\in\\{0,1\\}$, and a Wishart prior for the inverse of $\\Sigma$ \\cite{GelmanHill}.\n\n\n\\section{Simulation study}\\label{Sec:sim}\n\n We use a factorial simulation study to assess the finite sample performance of the alternative methods. The first factor is the proportion of participants who do not comply with the experimental regime, when assigned to it, expressed as a percentage of the total (one-sided non-compliance). Bias is expected to increase with increasing levels of non-compliance.  A systematic review \\cite{Dodd2012}  found that the percentage of non-compliance was less than 30\\% in two-thirds of published RCTs, but greater than 50\\% in one-tenth of studies. Here, two levels of non-compliance are chosen,  30\\% and 70\\%. As costs are typically skewed, three different distributions (Normal, Gamma or Inverse Gaussian -- IG) are used to simulate cost data. As the 2sls approach fails to accommodate the correlation between the endpoints, we examined the impact of different levels of correlation on the methods' performance; $\\rho$ takes one of four values $\\pm 0.4,\\ \\pm 0.8$. The final factor is the sample size of the RCT, taking two settings $n= 100, \\text{and}\\  1000$. In total, there are $2\\times 3\\times 4 \\times 2=48$ simulated scenarios.\n\nTo generate the data, we begin by simulating  $U\\sim N(0.50, 0.25^2)$,  independently from treatment allocation. $U$ represents a pre-randomisation variable that is a common cause of both the outcomes and the probability of non-compliance, {\\textsl{i.e.}\\ } it is a confounding variable, which we assume is unobserved.\n\nNow, let $S_i\\sim \\mbox{Bern}(\\pi_s)$ be the random variable denoting whether the $i$th individual switches from allocated active treatment to control. The probability $\\pi_s$ of one-way non-compliance with allocated treatment depends on $U$, in the following way,\n\n", "itemtype": "equation", "pos": 23619, "prevtext": "\n This model is a bivariate version of the `unadjusted Bayesian' method previously proposed for Mendelian randomisation \\cite{Burgess2012}. The causal treatment effect for outcome $Y_\\ell$, with $\\ell\\in\\{1,2\\}$, is represented by  $\\beta_{1,\\ell}$ in equations \\eqref{uBN}.\n\nFor the implementation, we express  $\\beta_{2,2}= \\rho\\frac{ \\sigma_2 }{\\sigma_1}$, and assume a vague normal prior $N(0, 10^2)$ on the Fisher's z-transform of $\\rho$. We also use vague normal priors for each regression coefficient  {\\textsl{i.e.}\\ } $\\beta_{m,j}\\sim N(0, 10^2)$, for $j \\in\\{0,1,2\\}, m\\in\\{0,1\\}$. For standard deviations, we use $\\sigma_j\\sim\\mbox{Unif}(0,10)$, for $j \\in\\{0,1,2\\}$.\n\n\nNext, we relax the normality assumption of equation \\eqref{uBN}, by modelling $Y_1$ ({\\textsl{i.e.}\\ } cost) with a Gamma distribution, and treatment received (binary), with a logistic regression. The health outcomes, $Y_2$, are still modelled with a normal distribution, as is customary. Because we are using a non-linear model for the treatment received, we use the predicted raw residuals from this model as extra regressors in the outcome models, similar to the 2-stage residual inclusion estimator \\cite{Terza2008}. We model  $Y_1$ by its marginal distribution (Gamma) and  $Y_2$ by a conditional Normal distribution, given $Y_1$ \\cite{Nixon2005}. We call this model `unadjusted Bayesian Gamma-Normal' (uBGN)  and write it as follows\n\\begin{eqnarray}\\label{equBGN}\n\\begin{array}{l}\n\\nonumber D_i \\sim \\mbox{Bern}(\\pi_{i}) \\\\\n\\nonumber Y_{1i}\\sim \\mbox{Gamma}(\\nu_{1i}, \\kappa_1)\\\\\nY_{2i}\\mid Y_{1i}\\sim N(\\mu_{2i}, {\\sigma^2}_2(1-\\rho^2)) \\\\\n\\end{array}\\ \\ \\ \\ \\ \\ \\ \\\n\\begin{array}{l}\n\\nonumber {\\text{logit}}(\\pi_{i})  = \\alpha_0 + \\alpha_1Z_i \\\\\n\\nonumber r_{i} = D_i-\\pi_i \\\\\n\\nonumber\\mu_{1i}= \\beta_{0,1}+ \\beta_{1,1} D_{i}+ \\beta_{1,r} r_{i} \\\\\n\\mu_{2i}= \\beta_{0,2}+\\beta_{1,2}D_{i}+ \\beta_{2,r} r_{i} +\\beta_{2,2} (y_{1i}-\\mu_{1i})\n\\end{array}\n\\end{eqnarray}\nwhere $\\mu_{1}=\\frac{\\nu_1}{\\kappa_1}$, is the mean of the Gamma distributed costs, with shape $\\nu_1$ and rate $\\kappa_1$.\n\nThe prior distribution for $\\nu_1$ is $\\mbox{Gamma}(0.01, 0.01)$. We also assume a Gamma prior for the intercept term of the cost equation, $\\beta_{0,1}\\sim\\mbox{Gamma}(0.01, 0.01)$.  All the other regression parameters have the same priors as those used in the uBN model.\n\n\nThe models introduced in this section, uBN and uBGN, are estimated in one stage, allowing feedback between the regression equations and the propagation of uncertainty.  However, these 'unadjusted' methods assume that the outcomes and the treatment received are independent, conditional on treatment allocation. The resulting bias in the causal estimate  $\\beta_{1,\\ell}$ is likely to be more important at higher levels of non-compliance.\n\n\\subsection{Bayesian IV with simultaneous equations (BFL)}\n\nWe now introduce an approach that models the covariance between treatment received and outcomes explicitly, using a  system of simultaneous equations. This can be done via full or limited information maximum likelihood, or by using MCMC to estimate the parameters in the model simultaneously allowing for proper Bayesian feedback and propagation of uncertainty. Here, we follow the Bayesian approach, assuming the endogenous variable  and the outcomes are all covariant and depend on the instrument.\nThis method is an extension of the `adjusted' Bayesian method presented in \\cite{Burgess2012}, equivalent to the expression for the IV unrestricted reduced form in \\cite{Kleibergen2003} and \\cite{Lancaster2004}.\n\nLet $(D_{i}, Y_{1i}, Y_{2i})^\\top$ be the transpose of vector of outcomes, which now includes treatment received, as well as the bivariate endpoints of interest.\nWe treat all three variables as multivariate normally distributed, so that\n \n", "index": 11, "text": "\\begin{equation}\n\\begin{array}{l}\n\\left(\\begin{array}{c}\nD_{i}\\\\ Y_{1i} \\\\ Y_{2i}\\end{array}\\right)\n\\sim N\\left\\{\\left(\\begin{array}{c}\n\\mu_{0i}\\\\\n\\mu_{1i}\\\\\n\\mu_{2i}\\end{array}\\right),  \\Sigma\\right\\}\n\\end{array}\\ \\ \\ \\ \\ \\ \\ \\\n\\begin{array}{l}\n\\Sigma= \\left(\\begin{array}{ccc} {\\sigma^2}_{0} & s_{01} & s_{02} \\\\  s_{01}& {\\sigma^2}_{1} & s_{12} \\\\\n s_{02}& s_{12} & {\\sigma^2}_{2}\n \\end{array} \\right)\n\\end{array}\n \\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E5.m1\" class=\"ltx_Math\" alttext=\"\\begin{array}[]{l}\\left(\\begin{array}[]{c}D_{i}\\\\&#10;Y_{1i}\\\\&#10;Y_{2i}\\end{array}\\right)\\sim N\\left\\{\\left(\\begin{array}[]{c}\\mu_{0i}\\\\&#10;\\mu_{1i}\\\\&#10;\\mu_{2i}\\end{array}\\right),\\Sigma\\right\\}\\end{array}\\ \\ \\ \\ \\ \\ \\ \\ \\begin{%&#10;array}[]{l}\\Sigma=\\left(\\begin{array}[]{ccc}{\\sigma^{2}}_{0}&amp;s_{01}&amp;s_{02}\\\\&#10;s_{01}&amp;{\\sigma^{2}}_{1}&amp;s_{12}\\\\&#10;s_{02}&amp;s_{12}&amp;{\\sigma^{2}}_{2}\\end{array}\\right)\\end{array}\" display=\"block\"><mrow><mtable displaystyle=\"true\"><mtr><mtd columnalign=\"left\"><mrow><mrow><mo>(</mo><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"center\"><msub><mi>D</mi><mi>i</mi></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>Y</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>Y</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr></mtable><mo>)</mo></mrow><mo>\u223c</mo><mrow><mi>N</mi><mo>\u2062</mo><mrow><mo>{</mo><mrow><mo>(</mo><mtable displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"center\"><msub><mi>\u03bc</mi><mrow><mn>0</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>\u03bc</mi><mrow><mn>1</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>\u03bc</mi><mrow><mn>2</mn><mo>\u2062</mo><mi>i</mi></mrow></msub></mtd></mtr></mtable><mo>)</mo></mrow><mo>,</mo><mi mathvariant=\"normal\">\u03a3</mi><mo>}</mo></mrow></mrow></mrow></mtd></mtr></mtable><mo mathvariant=\"italic\" separator=\"true\">\u2003\u2003\u2003\u2003</mo><mtable displaystyle=\"true\"><mtr><mtd columnalign=\"left\"><mrow><mi mathvariant=\"normal\">\u03a3</mi><mo>=</mo><mrow><mo>(</mo><mtable columnspacing=\"5pt\" displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"center\"><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>0</mn><none/></mmultiscripts></mtd><mtd columnalign=\"center\"><msub><mi>s</mi><mn>01</mn></msub></mtd><mtd columnalign=\"center\"><msub><mi>s</mi><mn>02</mn></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>s</mi><mn>01</mn></msub></mtd><mtd columnalign=\"center\"><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>1</mn><none/></mmultiscripts></mtd><mtd columnalign=\"center\"><msub><mi>s</mi><mn>12</mn></msub></mtd></mtr><mtr><mtd columnalign=\"center\"><msub><mi>s</mi><mn>02</mn></msub></mtd><mtd columnalign=\"center\"><msub><mi>s</mi><mn>12</mn></msub></mtd><mtd columnalign=\"center\"><mmultiscripts><mi>\u03c3</mi><none/><mn>2</mn><mn>2</mn><none/></mmultiscripts></mtd></mtr></mtable><mo>)</mo></mrow></mrow></mtd></mtr></mtable></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\nwhere $p$ denotes the corresponding average non-compliance percentage expressed as a probability, i.e here $p \\in \\{0.3, 0.7\\}$.\nWe now generate, $D_i$ the random variable of treatment received as\n\n", "itemtype": "equation", "pos": 26401, "prevtext": "\nwhere $s_{ij}=\\mbox{cov}(Y_i,Y_j)$, and\n\\begin{eqnarray}\\label{MVN_IVBayes}\n\\nonumber\\mu_{0i} &=& \\beta_{0,0} + \\beta_{1,0}Z_i \\\\\n\\nonumber\\mu_{1i} &=& \\beta_{0,1}+ \\beta_{1,1} \\beta_{1,0}Z_i  \\\\\n\\mu_{2i}&=&  \\beta_{0,2}+\\beta_{1,2}\\beta_{1,0}Z_i\n\\end{eqnarray}\nThe causal treatment effect estimates are $\\beta_{1,1}$ and $\\beta_{1,2}$ respectively.  For the implementation, we use vague normal priors for the regression coefficients, {\\textsl{i.e.}\\ } $\\beta_{m,j}\\sim N(0, 10^2)$, for $j \\in\\{0,1,2\\}, m\\in\\{0,1\\}$, and a Wishart prior for the inverse of $\\Sigma$ \\cite{GelmanHill}.\n\n\n\\section{Simulation study}\\label{Sec:sim}\n\n We use a factorial simulation study to assess the finite sample performance of the alternative methods. The first factor is the proportion of participants who do not comply with the experimental regime, when assigned to it, expressed as a percentage of the total (one-sided non-compliance). Bias is expected to increase with increasing levels of non-compliance.  A systematic review \\cite{Dodd2012}  found that the percentage of non-compliance was less than 30\\% in two-thirds of published RCTs, but greater than 50\\% in one-tenth of studies. Here, two levels of non-compliance are chosen,  30\\% and 70\\%. As costs are typically skewed, three different distributions (Normal, Gamma or Inverse Gaussian -- IG) are used to simulate cost data. As the 2sls approach fails to accommodate the correlation between the endpoints, we examined the impact of different levels of correlation on the methods' performance; $\\rho$ takes one of four values $\\pm 0.4,\\ \\pm 0.8$. The final factor is the sample size of the RCT, taking two settings $n= 100, \\text{and}\\  1000$. In total, there are $2\\times 3\\times 4 \\times 2=48$ simulated scenarios.\n\nTo generate the data, we begin by simulating  $U\\sim N(0.50, 0.25^2)$,  independently from treatment allocation. $U$ represents a pre-randomisation variable that is a common cause of both the outcomes and the probability of non-compliance, {\\textsl{i.e.}\\ } it is a confounding variable, which we assume is unobserved.\n\nNow, let $S_i\\sim \\mbox{Bern}(\\pi_s)$ be the random variable denoting whether the $i$th individual switches from allocated active treatment to control. The probability $\\pi_s$ of one-way non-compliance with allocated treatment depends on $U$, in the following way,\n\n", "index": 13, "text": "\\begin{equation}\n\\pi_s=\\begin{cases} p+0.1, \\text{if\\ } u>0.5,\\\\\np-0.1, \\text{otherwise}\n\\end{cases}\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E6.m1\" class=\"ltx_Math\" alttext=\"\\pi_{s}=\\begin{cases}p+0.1,\\text{if\\ }u&gt;0.5,\\\\&#10;p-0.1,\\text{otherwise}\\end{cases}\" display=\"block\"><mrow><msub><mi>\u03c0</mi><mi>s</mi></msub><mo>=</mo><mrow><mo>{</mo><mtable columnspacing=\"5pt\" displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"left\"><mrow><mrow><mrow><mrow><mi>p</mi><mo>+</mo><mn>0.1</mn></mrow><mo>,</mo><mrow><mtext>if\u00a0</mtext><mo>\u2062</mo><mi>u</mi></mrow></mrow><mo>&gt;</mo><mn>0.5</mn></mrow><mo>,</mo></mrow></mtd><mtd/></mtr><mtr><mtd columnalign=\"left\"><mrow><mrow><mi>p</mi><mo>-</mo><mn>0.1</mn></mrow><mo>,</mo><mtext>otherwise</mtext></mrow></mtd><mtd/></mtr></mtable></mrow></mrow></math>", "type": "latex"}, {"file": "1601.07127.tex", "nexttext": "\nwhere $Z_i$ denotes the random allocation for subject $i$.\n\nThen, the means for both outcomes are assumed to depend linearly on treatment received and the unobserved confounder $U$ as follows:\n\\begin{eqnarray}\\label{meancost}\\mu_1= E[Y_1]&=&1.2+ 0.4 D_i + 0.16(u_i - 0.5)\\\\\n\\mu_2=E[Y_2]&=&0.5+0.2 D_i + 0.04(u_i - 0.5)\n\\end{eqnarray}\n\nFinally, the bivariate outcomes are generated using Gaussian copulas, initially with normal marginals. In subsequent scenarios, we consider Gamma or Inverse Gaussian marginals for $Y_1$ and normal for $Y_2$. The conditional correlation between the outcomes, $\\rho$, is set according to the corresponding scenario.\n\nFor the scenarios where the endpoints are assumed to follow a bivariate normal distribution, the variances of the outcomes are set to ${\\sigma^2}_1=0.2^2, {\\sigma^2}_2=0.1^2$ respectively, while for scenarios with Gamma and IG distributed $Y_1$, the shape parameter is $\\eta=4$. For the Gamma case, this  gives a variance for $Y_1$ equal to ${\\sigma^2}_1=0.36$ in control and ${\\sigma^2}_1=0.64$ in the intervention group.  When $Y_1\\sim \\mbox{IG}(\\mu_1,\\eta)$, the expected variance in the control group is ${\\sigma^2}_1=0.432$, and ${\\sigma^2}_1=1.024$  in those receiving the intervention.\n\n\nThe simulated endpoints represent cost-effectiveness variables that have been rescaled for computational purposes, with costs divided by $1000$, and QALYs by $0.1$, such that the true values are $\\pounds 400$ (incremental costs), and $0.02$ (incremental QALYs) and so with a threshold value of $\\lambda=\\pounds 30000$ per QALY,  the true causal INB is $\\pounds 200$.\n\nFor each simulated scenario, we obtained $M=2500$ sets.\nFor the Bayesian analyses, we  use the median of the posterior distribution as the `estimate' of the parameter of interest, and the standard deviation of the posterior distribution as the standard error. Equi-tailed 95\\% posterior credible intervals are also obtained. We use the term confidence interval for the Bayesian credible intervals henceforth, to have a unified terminology for both Bayesian and frequentist intervals.\n\nOnce the corresponding causal estimate has been obtained in each of the 2500 replicated sets under each scenario in turn, we compute the median bias of the estimates, coverage of 95\\% confidence intervals (CI), median CI width and root mean square error (RMSE).  We report median bias as opposed to mean bias, because the BFL leads to a posterior distribution of the causal parameters which is Cauchy-like \\cite{Kleibergen2003}.\nWe judge a method's performance as `adequate', if it results in low levels of bias (median bias <5\\%) with coverage rates within 2.5\\% of the nominal value.\n\n\\textit{Implementation:}\\\\\nThe 3sls was fitted using \\texttt{systemfit} package in R using FGLS, and the Bayesian methods were run using JAGS from R \\texttt{(r2jags)}. Two chains, each one with 5000 initial iterations and 1000 burn-in were used. The multiple chains allowed for a check of convergence by the degree of their mixing and the initial iterations enabled to estimate iteration autocorrelation. A variable number of further 1000-iteration runs were performed until convergence was reached as estimated by the absolute value of the Geweke statistics for the first 10\\% and last 50\\% of iterations in a run being below 2.5. A final additional run of 5000 iterations was performed for each chain to achieve a total sample of 10000 iterations, and a MC error of about 1\\% of the parameter SE on which to base the posterior estimates.\nFor the uBGN,  an offset of  0.01 is added to the shape parameter $\\nu_1$ for the Gamma distribution of the cost,  to prevent the sampled shape parameter to become too close to zero, which may result in infinite densities. See the supplementary material for the JAGS model code.\n\n\n\\subsection{Simulation Study Results}\n\\textbf{\\textit{Bias}}\\\\\nFigure \\ref{30Biasplot} shows the median bias corresponding to scenarios with 30\\% non-compliance, by cost distributions (left to right) and levels of correlation between the two outcomes, for sample sizes of $n=100$ (upper panel) and $n=1000$ (lower panel).\n With the larger sample size, for all methods, bias is negligible with normally distributed costs, and remain less than 5\\% when costs are Gamma-distributed. However, when costs follow an Inverse Gaussian distribution, and the absolute levels of correlation between the endpoints are high ($\\pm 0.8$), the uBGN approach results in biased estimates, around 10\\% bias for the estimated incremental cost, and between 20 and 40\\% for the estimated INB. With the small sample size and when costs follow a Gamma or Inverse Gaussian distribution, both unadjusted Bayesian methods provide estimates with moderate levels of bias.\n\nFigure \\ref{70Biasplot}, corresponding to 70\\% non-compliance, shows the unadjusted methods resulting in important biases, which persist even with large sample sizes, especially for scenarios with non-normal outcomes. For small sample settings, uBN reports positive bias (10 to 20\\%) in the estimation of incremental QALYs, and the resulting INB, irrespective of the cost distribution. The uBGN method reports relatively unbiased estimates of the QALYs, but large positive bias (up to 60\\%) in the estimation of costs, and hence, there is substantial bias in the estimated INB (up to 200\\%).  Unadjusted Bayesian methods estimates are biased in the direction of the true causal effect, because these methods ignore the positive correlation between treatment received and each outcome introduced by the confounding variable.  By contrast, the BFL and the 3sls provide estimates with low levels of bias across most settings.\n\n\\clearpage\n\\afterpage{\n\\begin{figure}\n\\begin{center}\n\\caption{\\footnotesize{Median Bias for scenarios with  30\\% non-compliance and sample sizes of (a) $n=100$ (top) and (b)  $n=1000$. Results are stratified by cost distribution, and correlation between cost and QALYs. The dashed lines represents the $\\pm 5\\%$} bias while the dotted line represents zero bias. Results for 2sls (not plotted) are identical to those for 3sls; uBGN was not applied to Normal cost data.}\\label{30Biasplot}\n\\vskip -.3ex\n\\subfloat[n=100]{\\includegraphics[scale=.5]{bias_plot_nc30s100.eps}}\\\\\\vskip -.51ex\n\\subfloat[n=1000]{\\includegraphics[scale=.5]{bias_plot_nc30s1000.eps}}\n\\vskip -.7ex\n\\end{center}\n\\end{figure}\n}\n\\clearpage\n\\begin{figure}\n\\begin{center}\n\\caption{\\footnotesize{Median Bias for scenarios with  70\\% non-compliance and sample sizes of (a) $n=100$ (top) and (b)  $n=1000$. Results are stratified by cost distribution, and correlation between cost and QALYs. The dashed lines represents the $\\pm 5\\%$} bias while the dotted line represents zero bias. Results for 2sls (not plotted) are identical to those for 3sls; uBGN was not applied to Normal cost data.}\\label{70Biasplot}\n\\vskip -.3ex\n\\subfloat[n=100]{\\includegraphics[scale=.5]{bias_plot_nc70s100.eps}}\\\\ \\vskip -.5ex\n\\subfloat[n=1000]{\\includegraphics[scale=.5]{bias_plot_nc70s1000.eps}}\n\\vskip -.7ex\n\\end{center}\n\\end{figure}\n\n\n\\vskip 1ex\n\\textbf{\\textit{CI coverage and width}}\\\\\nTable \\ref{CI30modcorr} presents the results for CI coverage and width, for scenarios with a sample size of $n=100$, absolute levels of correlation between the endpoints of 0.4, and 30\\% non-compliance. All other results are shown in the Appendix.\n\nThe 2sls approach ignores the correlation between costs and QALYs, and thus, depending on the direction of this correlation, 2sls reports CI coverage that is above (positive correlation) or below (negative correlation) nominal levels. This divergence from nominal levels increases with higher absolute levels of correlation (see Appendix, Table \\ref{CI30highcorr}).\n\nThe uBN approach results in over-coverage across many settings, with wide CIs. For example, for both levels of non-compliance and either sample size, when the costs are Normal, the CI coverage rates for both incremental costs and QALYs exceed 0.98. The argument given by Burgess and Thompson \\cite{Burgess2012} can be adapted here to explain this: assuming that the treatment received and the outcomes are uncorrelated,  when the true correlation between the treatment received and the outcomes is positive, leads to over-estimation of the variance and wide confidence intervals.\n\n By contrast, the uBGN method results in low CI coverage rates for the estimation of incremental costs, when costs follow an inverse Gaussian distribution. This is because the model incorrectly assumes a Gamma distribution, therefore underestimating the variance. The extent of the under-coverage appears to increase with increasing absolute values of the correlation between the endpoints, with coverage as low as 0.68 (incremental costs) and 0.72 (INB)  in scenarios where the absolute value of correlation between costs and QALYs is 0.8. (see Appendix, Table \\ref{CI30highcorr1000}).\n\nThe BFL approach reports estimates with CI coverage close to the nominal when the sample size is large, but with excess coverage (greater than 0.975), and relatively wide CI, when the sample size is $n=100$, (see Table \\ref{CI30modcorr} for 30\\% noncompliance, and Table \\ref{CI70modcorr} in Appendix for the result corresponding to 70\\% non-compliance).  By contrast, the 3sls reports CI coverage within 2.5\\% of nominal levels for each sample size, level of non-compliance, cost distribution and level of correlation between costs and QALYs.\n\\vskip 1ex\n\\textbf{\\textit{RMSE}}\\\\\nTable  \\ref{rmse30N100} reports RMSE corresponding to 30\\% non-compliance, and $n=100$.  The least squares approaches result in lower RMSE than the other methods for the summary statistic of interest, the INB.  This pattern is repeated across other settings, see Appendix, Tables \\ref{rmse30N100_high}-- \\ref{rmse70N1000_high}.\n\n\\section{Results for the motivating example}\\label{Sec:RefluxCACE}\n We now apply each  method to the REFLUX dataset, to illustrate and compare the methods in practice. For the implementation of the Bayesian approaches, we use two chains, initially running 15000 iterations with 5000 burn-in. After checking visually for auto-correlation, an extra 10000 iterations are needed to ensure that the density plots of the parameters corresponding to the two chains are very similar, denoting convergence to the stationary distribution. The last 5000 iterations for each chain are kept, making the total sample equal to 10000. The priors are vague normal priors as specified in each of the Bayesian methods above. For comparability with the frequentist approach, all Bayesian analyses are run on the complete cases. We report incremental costs, QALYs and INB for receipt of surgery versus medical management.\n\nTable \\ref{TableReflux1} shows that, for the motivating example, the CACEs are similar across the methods.  The conclusion is that, amongst the compliers, those receiving surgery had a larger gain in average QALYs for an additional cost; receipt of surgery was cost-effective versus medical management, with a positive INB, albeit with 95\\% CIs that included zero.\n\n\\section{Discussion}\\label{Sec:Discussion}\nIn this paper, we compared alternative approaches for estimating CACEs in RCTs with non-compliance and multivariate outcomes. Across all the settings considered, the 3sls approach reports unbiased estimates for the INB and unlike 2sls, provides CI coverage close to nominal levels for the main statistic of interest, the INB. We also explored three Bayesian methods,  with the Full Likelihood approach resulting in low levels of bias, and CI coverage close to nominal levels throughout. By contrast, the `unadjusted Bayesian' methods resulted in biased estimates and poor coverage.\n\nThis paper builds on previous work which has proposed Bayesian approaches to IV estimation for univariate continuous outcomes. Burgess and Thompson \\cite{Burgess2012} found the BFL was median unbiased and gave CI coverage close to nominal levels, albeit with wider CIs than least-squares methods. When the instrument is weak, BFL methods result in smaller bias than 2sls methods. Their `unadjusted Bayesian' method, similar to our uBN approach, assumes that the treatment received is uncorrelated with the outcome, given the treatment allocation. This results in bias in the direction of the true association, and affects the CI coverage. Our simulation study shows that, in a setting with multivariate outcomes, the bias can be substantial.\n\nA potential concern for the proposed Bayesian methods is the choice of priors. Our choice of weakly informative priors, which were relatively flat in the region where the values of the parameters were anticipated to be, together with samples of at least size 100, should limit the influence of the priors on the posterior estimates.\n\nWe also proposed a 3sls method for estimating the CACE in RCTs with multivariate outcomes. In our simulations, we found that 3sls method performed well even with sample sizes as small as 100, and with non-normal continuous outcomes. The well-documented weak-instrument bias that occurs in least-square estimation of CACE  was not a concern here, as even with 70\\% levels of non-compliance, randomisation is a `strong' instrument.  We find that the performance of the BFL and 3sls is similar throughout, and either of these approaches is therefore appropriate for the range of settings considered here, namely, RCTs with non-compliance levels of up to 70\\%, skewed costs, sample sizes as low as 100, and irrespective of the levels of correlation between the outcomes. One considerable practical advantage of 3sls is that the method is already implemented in widely available software packages (R and Stata) and the computation time is minimal. By contrast, the BFL approach needs to be specified carefully. That said, a relative advantage of the BFL is that it can directly handle missing data, and could be extended relatively easily to hierarchical settings, whereas the 3sls approach would need modifications to handle these explicitly.\n\nThis paper extends existing methods for CEA \\cite{Willan2003,Nixon2005}, by providing IV methods for obtaining causal cost-effectiveness estimates in the presence of non-compliance.  We find that applying 2sls separately to the univariate outcomes leads to inaccurate 95\\% CI around the INB, even with moderate levels of correlation between costs and outcomes ($\\pm 0.4$).\nAnother alternative for estimating CACE of the INB with appropriate confidence intervals, would be to estimate separate CACEs for incremental costs and health outcomes, and then use a bootstrap procedure to account for the correlation between the endpoints, by resampling with replacement pairs of costs and health outcomes.  However, previous studies have shown that non-parametric bootstrap methods provide inefficient estimates of incremental costs, QALYs and INB, in settings with right-skewed costs and small sample sizes \\cite{Nixon2010}.\n\n\nAs with any simulation study, the range of scenarios could not encompass all the possible problems encountered in practice. It should be recognised that these findings apply to settings where a linear additive treatment effect is of interest, and like previous studies comparing alternative IV estimation approaches, we assume that the requisite assumptions for identification are met. Weak instruments settings have been ignored because for binary non-compliance with randomised binary allocation, the percentage of one-way non-compliance would need to be in excess of 85\\%, for the F-statistic of the randomization instrument to be less than 10, the traditional cutoff beneath which an instrument is regarded as 'weak'. Such levels of non-compliance are not realistic in practice, with the reported  median non-compliance equal to 12\\% \\cite{Zhang2014}.\nAlso, for simplicity, we assumed that those in the control arm did not have access to the active treatment. In the motivating example, we show how the methods can handle two-way non-compliance without further modification. Since this RCT had lower levels of non-compliance than those considered in the simulation study, we conclude that provided the other IV assumptions hold, then either the BFL or 3sls provide unbiased estimates of the CACE for cost-effectiveness, with 95\\% CIs attaining close to nominal coverage.\n\n\nFuture research directions could include exploiting the additional flexibility of the Bayesian framework to incorporate informative priors, perhaps as part of a comprehensive decision modelling approach. The methods developed could also be potentially extended to handle time-varying non-compliance.\n\n\\clearpage\n\\begin{center}\n\\begin{threeparttable}\n  \\caption{The REFLUX study: descriptive statistics, estimated cost-effectiveness according to ITT and alternative methods for estimating the CACE.}\\label{TableReflux1}\n\\begin{tabular}{rrr}\\hline \\hline\n          & Medical management & Laparoscopic surgery \\\\\n    N Assigned\\tnote{a} & $88$    & $84$ \\\\\n    N (\\%) Switched\\tnote{b} & $1$ $(1.14)$ & $18$  $(21.43)$ \\\\\n    Mean (SD) cost in \\pounds & $1316\\  (1728)$ & $2982\\  (1813)$ \\\\\n    Mean (SD) QALYs  & $3.52\\  (0.99)$ & $3.74 \\ (0.90)$ \\\\\n    Correlation between costs and QALYs   & $-0.42$ & $-0.07$ \\\\\n  \n\\\\ \\hline \\hline\n        \\multicolumn{3}{c}{\\textbf{Incremental costs, QALYs and INB of surgery vs medicine\\tnote{c}}}  \\\\ \\hline \\hline\nOutcome  &Method        & estimate  ( 95\\% CI )\\\\\n \\hline\nIncremental cost\\tnote{d} &&\\\\\n \\hline\n& ITT& $1665\\ (1137,  2195)$\\\\\n& 2sls &$2151\\ (1532, 2771)$\\\\\n& 3sls &$2151\\ (1531, 2771)$\\\\\n&uBN &$2163\\ (1434, 2933)$ \\\\\n&uBGN &$1919 \\ (1135, 2681)$\\\\\n&BFL&$1999\\ (1383, 2594)$\\\\\n\n\\hline\nIncremental QALYs&&\\\\\n \\hline\n\n& ITT &  $0.212\\ (-0.073, 0.500)$ \\\\\n& 2sls& $0.274\\ (-0.094,0.643)$\\\\\n& 3sls& $0.274\\ (-0.094,0.643)$\\\\\n& uBN &$0.277\\ (-0.099,0.661)$ \\\\\n&uBGN &$  0.288 \\ (-0.077,  0.659)$\\\\\n&   BFL&  $0.300\\ (-0.061, 0.680)$\\\\\n \\hline\nINB\\tnote{d, \\ e}& &\\\\\n \\hline\n& ITT & $4709\\ (-3994,  13412)$ \\\\\n& 2sls& $6081\\  (-4999, 17161)$ \\\\\n& 3sls  & $6081\\  (-5181, 17344)$ \\\\\n& uBN &$6106\\ (-5357, 17816)$ \\\\\n&uBGN &$ 6721\\  (-4448, 18089)$\\\\\n& BFL &     $7027\\ (-4044, 18540)$ \\\\ \\hline\n  \\end{tabular}\n\\begin{tablenotes}\n  \\footnotesize{\n\\item [a] Statistics reported are for complete cases.\\\\\n\\item [b] Defined within the first year post randomisation.\\\\\n\\item [c] The incremental costs, QALYs and INB are reported over a time horizon of five years.\\\\\n\\item [d] Numbers rounded to the nearest integer.\\\\\n\\item [e] The willingness to pay used was $\\lambda= \\pounds 30000$.}\n   \\end{tablenotes}\n\\end{threeparttable}\n\\end{center}\n\n\n\n\\clearpage\n\n\\begin{sidewaystable}[h]\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental cost, QALYs, and INB, across scenarios with 30\\% non-compliance, moderate correlation between outcomes and sample size $n= 100$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{lcrrrrrrrrrrr} \\hline\n    \n    \\textbf{} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}} & \\multicolumn{2}{c}{\\textbf{2sls}} & \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}} &\\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n    \\textbf{Cost distribution} & \\textbf{} & \\textbf{$\\rho$}   & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &&&       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4  &  0.946 & 0.112 &  0.946 & 0.112 & 0.992 & 0.312 & &&0.988 & 0.299 \\\\\n    \\textbf{} & \\textbf{} & -0.4 &  0.946 & 0.113 & 0.950  & 0.113 & 0.993 & 0.325 & &&0.986 & 0.297 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} &       &       &     &&  &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4  &  0.952 & 0.228 &  0.952 & 0.228 & 0.988 & 0.155 & &&0.950  & 0.121 \\\\\n    \\textbf{} & \\textbf{} & -0.4 &  0.952 & 0.229 &  0.952 & 0.229 & 0.992 & 0.163 & &&0.950  & 0.121 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &       &       &       &&&       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4 &  0.988 & 405  &  0.953 & 319   & 0.982 & 398   & &&0.966 & 376 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &0.900   & 409  & 0.948 & 475   & 0.951 & 509   & &&0.962 & 525 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost}&& &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4   & 0.959 & 0.113  & 0.959 & 0.113 & 0.955 & 0.815 &0.941 & 0.818 & 0.954 & 0.823 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.959 & 0.113 & 0.949 & 0.113 & 0.949 & 0.828 & 0.936 & 0.822  & 0.945 & 0.811 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4   & 0.952 & 0.756 & 0.952 & 0.756 & 0.993 & 0.160& 0.960 & 0.122  & 0.960  & 0.122 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.942 & 0.759  & 0.942 & 0.759 & 0.995 & 0.163& 0.954 & 0.122  & 0.954 & 0.122 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4      & 0.982 & 829 & 0.948 & 696   & 0.958 & 764& 0.942 & 748   & 0.956 & 760 \\\\\n    \\textbf{} & \\textbf{} & -0.4     & 0.914 & 833& 0.948 & 943   & 0.930  & 921 & 0.941 & 1019   & 0.951 & 1014 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{Gaussian} & \\textbf{}  & 0.4 & 0.945& 0.112 & 0.945 & 0.112 & 0.958 & 0.949& 0.904 & 0.866 & 0.956 & 0.945 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.954 & 0.112 & 0.954 & 0.112 & 0.958 & 0.951& 0.905 & 0.864 & 0.954 & 0.932 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4     & 0.951 & 0.88& 0.951 & 0.880  & 0.991 & 0.161& 0.944 & 0.120 & 0.999 & 0.206 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.950  & 0.878 & 0.950  & 0.878 & 0.993 & 0.161& 0.952 & 0.120 & 0.999 & 0.204 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &     &&  &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.4     & 0.980  & 944 & 0.954 & 818   & 0.959 & 889&0.917& 814  & 0.984 & 1001 \\\\\n    \\textbf{} & \\textbf{} & -0.4    &  0.917 & 942&0.947 & 1049  & 0.934 & 1034  & 0.911 & 1041 & 0.971 & 1203 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI30modcorr}\n\\end{sidewaystable}\n\n\\clearpage\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 30\\% non-compliance, moderate correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n     \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}}& \\multicolumn{1}{c}{\\textbf{uBGN}} & \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.029 & 0.060 & & 0.059 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.029 & 0.062 & &0.061 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &      &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.058 & 0.030 & &0.030 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.060 & 0.030 & &0.030\\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 83  & 84  & &87 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 125 & 127 & &125 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4    & 0.030 & 0.202 & 0.212& 0.202 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.029 & 0.204 & 0.212& 0.203 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.198 & 0.030 &0.030& 0.029 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.200   & 0.030 & 0.030& 0.030 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  181   & 184 &193  & 184 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 246   & 251 &261  & 252 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.4   & 0.029 & 0.232 &0.252& 0.232 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.029 & 0.232 &0.250& 0.232 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.230& 0.030 &0.030& 0.030\\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.230 & 0.030 &0.030& 0.030 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 211   & 214   & 231&214 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 273   & 278 &296  & 278 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse30N100}\n\\end{table}\n\n\\clearpage\n\n\\begin{thebibliography}{unsrt}\n\n\n\\bibitem{Angrist1996}\n  {Angrist}, J.~D.,{Imbens}, G.~W.,   {Rubin}, D.~B.\n\\newblock Identification of causal effects using instrumental variables.\n\\newblock {\\em Journal of the American Statistical Association}, 91(434):pp.\n  444--455, 1996.\n\n\\bibitem{Baiocchi2014}\n  {Baiocchi}, M., {Cheng}, J., {Small}, D.~S.\n\\newblock Instrumental variable methods for causal inference.\n\\newblock {\\em Statistics in Medicine}, 33(13):2297--2340, 2014.\n\n\\bibitem{NICE}\n{NICE}\n\\newblock {\\em {M}ethods for {T}echnology {A}ppraisal.}\n\\newblock National Institute for Health and Clinical Excellence, London, UK. 2013.\n\n\n\\bibitem{Latimer2014}\n {Latimer}, N.~R., {Abrams}, K.~R., {Lambert}, P.~C.,\n   {Crowther}, M.~J., {Wailoo}, A.~J., {Morden}, J.~P.,\n   {Akehurst}, R.~L., {Campbell}, M.~J.\n\\newblock Adjusting for treatment switching in randomised controlled trials - a\n  simulation study and a simplified two-stage method.\n\\newblock {\\em Statistical Methods in Medical Research},  0962280214557578, 2014.\n\n\\bibitem{Brilleman2015}\n{Brilleman}, S.~L., {Metcalfe}, C., {Peters}, T.~J.,  {Hollingsworth}, W.\n\\newblock The reporting of treatment non-adherence and its associated impact on\n  economic evaluations conducted alongside randomised trials: a systematic\n  review.\n\\newblock {\\em Value in Health}, (in press), 2015.\n\n\\bibitem{Willan2003}\n {{W}illan}, {A}.~{R}., {{C}hen}, {E}.,  {{C}ook},\n  {R}.~{J}., {{L}in}, {D}.~{Y}.\n\\newblock {I}ncremental net benefit in randomized clinical trials with\n  qualify-adjusted survival.\n\\newblock {\\em Statistics in Medicine}, 22:353--362, 2003.\n\n\\bibitem{Willan2006a}\n {{W}illan}, {A}.\n\\newblock {S}tatistical {A}nalysis of cost-effectiveness data from randomised\n  clinical trials.\n\\newblock {\\em Expert Revision Pharmacoeconomics Outcomes Research},\n  6:337--346, 2006.\n\n\\bibitem{Zellner1963}\n {Zellner}, A., {Theil}, H.\n\\newblock Three-stage least squares: Simultaneous estimation of simultaneous\n  equations.\n\\newblock {\\em Econometrica}, 30(1):pp. 54--78, 1962.\n\n\\bibitem{Burgess2012}\n{Burgess}, S.,  {Thompson}, S.~G.\n\\newblock Improving bias and coverage in instrumental variable analysis with\n  weak instruments for continuous and binary outcomes.\n\\newblock {\\em Statistics in Medicine}, 31(15):1582--1600, 2012.\n\n\\bibitem{Kleibergen2003}\n {Kleibergen}, F., {Zivot}, E.\n\\newblock Bayesian and classical approaches to instrumental variable\n  regression.\n\\newblock {\\em Journal of Econometrics}, 114(1):29 -- 72, 2003.\n\n\\bibitem{Grant2008}\n{Grant}, A.,  {Wileman}, S.,  {Ramsay}, C.,  {Boyke},\n  L.,  {Epstein}, D., {Sculpher}, M.\n\\newblock The effectiveness and cost-effectiveness of minimal access surgery\n  amongst people with gastro-oesophageal reflux disease- a uk collaborative\n  study. the reflux trial.\n\\newblock {\\em Health Technology Assessment}, 12 (31), 2008.\n\n\\bibitem{Grant2008a}\n{Grant}, A., {Wileman}, S.,  {Ramsay}, C.,  {Mowat}, N.,  {Krukowski}, Z.,\n   {Heading}, R.,  {Thursz}, M.,  {Campbell},  M.\n\\newblock Minimal access surgery compared with medical management for chronic\n  gastro-oesophageal reflux disease: {UK} collaborative randomised trial.\n\\newblock {\\em BMJ}, 337, 2008.\n\n\\bibitem{Grant2013}\n{Grant}, A., {Boachie}, C.,  {Cotton}, S., {Faria}, R., {Bojke}, L.,  {Epstein}, D.\n\\newblock Clinical and economic evaluation of laparoscopic surgery compared\n  with medical management for gastro-oesophageal reflux disease: a 5-year\n  follow-up of multicentre randomised trial (the reflux trial).\n\\newblock {\\em Health Technology Assessment}, 17(22), 2013.\n\n\\bibitem{AngristBook} {Angrist}, J.~D., {Pischke}, J.~S.\n  \\newblock {\\em Mostly Harmless Econometrics: An Empiricist's Companion}.\n  \\newblock {Princeton University Press}.\n  \\newblock {2008}.\n\n\\bibitem{Zellner1962}\n {Zellner}, A.\n\\newblock An efficient method of estimating seemingly unrelated regressions and\n  tests for aggregation bias.\n\\newblock {\\em Journal of the American Statistical Association}, 57(298):pp.\n  348--368, 1962.\n\n\\bibitem{Willan2004}\n{{W}illan}, {A}.~{R}.,  {{B}riggs}, {A}.~{H}., {{H}och}, {J}.~{S}.\n\\newblock {R}egression methods for covariate adjustment and subgroup analysis\n  for non-censored cost-effectiveness data.\n\\newblock {\\em Health Econ.}, 13(5):461--75, 2004.\n\n\n\\bibitem{Greene2002}\n{Greene}, W.~H.\n\\newblock {\\em Econometric Analysis}.\n\\newblock Prentice-Hall international editions. Prentice Hall, 2002.\n\n\\bibitem{Schmidt1990}\n{Schmidt}, P.\n\\newblock Three-stage least squares with different instruments for different\n  equations.\n\\newblock {\\em Journal of Econometrics}, 43(3):389 -- 394, 1990.\n\n\\bibitem{Nixon2005}\n {{N}ixon}, {R}.~{M}., {{T}hompson}, {S}.~{G}.\n\\newblock {Methods for incorporating covariate adjustment, subgroup analysis\n  and between-centre differences into cost-effectiveness evaluations.}\n\\newblock {\\em Health economics}, 14(12):1217--29, December 2005.\n\n\\bibitem{Terza2008}\n{Terza}, J.~V., {Basu}, A., {Rathouz},\n  P.~J.\n\\newblock Two-stage residual inclusion estimation: Addressing endogeneity in\n  health econometric modeling.\n\\newblock {\\em Journal of Health Economics}, 27(3):531 -- 543, 2008.\n\n\\bibitem{Lancaster2004}\n {Lancaster}, T.\n\\newblock {\\em Introduction to Modern Bayesian Econometrics}.\n\\newblock Wiley, 2004.\n\n\\bibitem{GelmanHill}\n{Gelman}, A., {Hill}, J.\n\\newblock {\\em Data Analysis Using Regression and Multilevel/Hierarchical\n  Models}.\n\\newblock Analytical Methods for Social Research. Cambridge University Press,\n  2006.\n\n\n\\bibitem{Dodd2012}\n{Dodd}, S., {White}, I., Williamson, P.\n\\newblock {Nonadherence to treatment protocol in published randomised controlled\n  trials: a review.}\n\\newblock \\emph{Trials} 13 (1):84, 2012.\n\n\n\\bibitem{Nixon2010}\n {Nixon}, R., {Wonderling}, D., {Grieve}, R.~\n\\newblock Non-parametric methods for cost-effectiveness analysis: the central\n  limit theorem and the bootstrap compared.\n\\newblock {\\em Health Economics}, 19(3):316--333, 2010.\n\n\\bibitem{Zhang2014}\n {Zhang}, Z.,  {Peluso}, M.~J.,  {Gross}, C.~P.,\n   {Viscoli}, C.~M., {Kernan}, W.~N.\n\\newblock Adherence reporting in randomized controlled trials.\n\\newblock {\\em Clinical Trials}, 11(2):195--204, 2014.\n\n\\end{thebibliography}\n\n\n\\clearpage\n\\section{Appendix}\n\n\\begin{sidewaystable}\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 30\\% non-compliance, moderate correlation between outcomes and sample size $n= 1000$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n    \n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}}  & \\multicolumn{2}{c}{\\textbf{2sls}} &\\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}& \\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\\\cline{4-13}\n  \\textbf{Cost distribution} & \\textbf{} & \\textbf{$\\rho$}   & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} \\\\ \\hline\n \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &   &    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4 & 0.942 & 0.036  & 0.942 & 0.036 & 0.989 & 0.094 & && 0.956 & 0.075 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  &  0.947 & 0.036 & 0.947 & 0.036 & 0.992 & 0.097 & &&0.963 & 0.075 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &     &  &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4  &   0.949 & 0.072 &   0.949 & 0.072 & 0.982 & 0.046 & &&0.937 & 0.035 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.957 & 0.072 & 0.957 & 0.072 & 0.991 & 0.048 & &&0.944 & 0.035 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &  &     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4 &0.986 & 129  & 0.951 & 102   & 0.977 & 120   & &&0.950  & 101 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  &0.920 & 129&  0.956 & 150   & 0.962 & 155   & &&0.949 & 149 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost} &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.947 & 0.036 & 0.947 & 0.036 & 0.955 & 0.246 & 0.943 & 0.235 &  0.951 & 0.242 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.950  & 0.036 & 0.950  & 0.036 & 0.958 & 0.248 & 0.945 & 0.235& 0.954 & 0.243 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &       &       &      & &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   &  0.949 & 0.240 &  0.949 & 0.240  & 0.990  & 0.048 & 0.946 & 0.036& 0.943 & 0.035 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  &   0.953 & 0.240  &   0.953 & 0.240  & 0.993 & 0.048& 0.949 & 0.036 & 0.950  & 0.036 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &       &&       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4 & 0.985 & 262  &  0.950  & 221   & 0.957 & 229 & 0.944 & 218   & 0.949 & 221 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4 & 0.920 & 262 & 0.952 & 297   & 0.932 & 276   & 0.946 & 292 &  0.954 & 301 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost} &  &     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.4  &  0.954 & 0.036  &  0.954 & 0.036 & 0.958 & 0.290& 0.902 & 0.248  & 0.947 & 0.281 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  &  0.949 & 0.036&  0.949 & 0.036 & 0.957 & 0.291& 0.901 & 0.249 & 0.946 & 0.277 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4  &  0.949 & 0.283 &  0.949 & 0.283 & 0.990  & 0.048 & 0.942 & 0.035& 0.967 & 0.038\\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  &  0.952 & 0.283&  0.952 & 0.283 & 0.989 & 0.048 & 0.942 & 0.035 & 0.961 & 0.038 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.976 & 303  &  0.956 & 263   & 0.958 & 268 & 0.914 & 235   & 0.958 & 268 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.922 & 302&  0.950  & 336   & 0.932 & 315& 0.906 & 300   & 0.947 & 333 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI30modcorr1000}\n\\end{sidewaystable}\n\n\\clearpage\n\n\\begin{sidewaystable}[h]\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70\\% non-compliance, moderate correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n  \n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}}& \\multicolumn{2}{c}{\\textbf{2sls}}  & \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}& \\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n \\textbf{Cost distribution} & \\textbf{} & \\textbf{$\\rho$}   & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} \\\\ \\hline\n     \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n\\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.968 & 0.271 & 0.968 & 0.271 & 0.988 & 1.33 && & 0.991 & 1.13 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.964 & 0.269 & 0.964 & 0.269 & 0.99  & 1.30   & &&0.985 & 1.08 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4     & 0.968 & 0.550 & 0.968 & 0.550  & 0.988 & 0.665 & &&0.964 & 0.445 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.966 & 0.545& 0.966 & 0.545 & 0.986 & 0.665 & &&0.954 & 0.435 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &    &&   &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.992 & 981    & 0.966 & 771   & 0.985 & 1453  & &&0.981 & 1411 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.917 & 973   & 0.966 & 1131  & 0.957 & 1788  & &&0.958 & 1912 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost}&& &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.972 & 0.267 & 0.972 & 0.267 & 0.964 & 2.640& 0.944 & 2.21  & 0.960  & 2.73 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.965 & 0.269 & 0.965 & 0.269 & 0.965 & 2.690  &  0.950 & 2.21& 0.964 & 2.71 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.966 & 1.68  & 0.966 & 1.68  & 0.994 & 0.624 & 0.959 & 0.348& 0.965 & 0.42 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4    & 0.969 & 1.69 & 0.969 & 1.69  & 0.987 & 0.625& 0.954 & 0.351& 0.954 & 0.42 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &    &&   &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.988 & 1870 & 0.966 & 1557  & 0.964 & 2456&0.947 & 2041& 0.970  & 2503 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4      & 0.939 & 1876 & 0.971 & 2138  & 0.947 & 2984&0.958 & 2774 & 0.962 & 3344 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.4   &  0.967 & 0.268 &  0.967 & 0.268 & 0.967 & 3.04& 0.912 & 2.29  & 0.972 & 3.31 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.966 & 0.271& 0.966 & 0.271 & 0.966 & 3.05  & 0.910 & 2.30&0.968 & 3.37 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   &  0.965 & 1.92&  0.965 & 1.92  & 0.988 & 0.637&0.948 & 0.355 & 1     & 0.766 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.958 & 1.90& 0.958 & 1.90   & 0.990  & 0.631&0.945 & 0.359 & 0.999 & 0.774 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4  & 0.990  & 2082 &  0.961 & 1777  & 0.963 & 2827 & 0.912 & 2157  & 0.991 & 3554 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.936 & 2071 &  0.970  & 2335  & 0.912 & 3389 &  0.924 & 2855 & 0.979 & 4819 \\\\ \\hline\n    \\end{tabular}\\label{CI70modcorr}\n\\end{sidewaystable}\n\n\n\n\\begin{sidewaystable}\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70\\% non-compliance, moderate correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n   \n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}} & \\multicolumn{2}{c}{\\textbf{2sls}} &\\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}& \\multicolumn{2}{c}{\\textbf{uBGN}}  & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n \\textbf{Cost distribution} & \\textbf{} & \\textbf{$\\rho$}   & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} \\\\ \\hline\n     \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &       &       &       &       &       &       &  &&     &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4  & 0.946 & 0.083 & 0.946 & 0.083 & 0.986 & 0.223 & && 0.958 & 0.178 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.953 & 0.083   & 0.953 & 0.083 & 0.991 & 0.230  & &&0.960  & 0.179 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.954 & 0.169& 0.954 & 0.169 & 0.986 & 0.111 &&& 0.942 & 0.084\\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.953 & 0.169& 0.953 & 0.169 & 0.992 & 0.115 &&& 0.947 & 0.083\\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &&&       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.986 & 301 & 0.948 & 238   & 0.976 & 287   & &&0.944 & 240 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.909 & 301 & 0.944 & 349   & 0.953 & 368   & &&0.942 & 356 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.951 & 0.083 & 0.951 & 0.0832 & 0.958 & 0.556 & 0.939 & 0.523 & 0.952 & 0.541 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.955 & 0.083 & 0.955 & 0.0832 & 0.958 & 0.556 & 0.943 & 0.524& 0.952 & 0.541 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.952 & 0.526& 0.952 & 0.526 & 0.995 & 0.115& 0.947 & 0.085 & 0.949 & 0.084 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4  & 0.952 & 0.525& 0.952 & 0.525 & 0.995 & 0.115  & 0.954 & 0.084& 0.955 & 0.085 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4    & 0.980 & 582   & 0.954 & 486   & 0.932 & 626& 0.946 & 487   & 0.951 & 496 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.916 & 581  & 0.953 & 661   & 0.932 & 626  &  0.944 & 662& 0.953 & 678 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.4  &0.943 & 0.083&0.943 & 0.083 & 0.959 & 0.621 & 0.909 & 0.538& 0.950  & 0.603 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.946 & 0.083& 0.946 & 0.083 & 0.96  & 0.629 &  0.910 & 0.542&0.948 & 0.599 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4  & 0.952 & 0.595& 0.952 & 0.595 & 0.991 & 0.114& 0.938 & 0.084 & 0.959 & 0.0918 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4& 0.955 & 0.599 &0.955 & 0.599 & 0.988 & 0.115 & 0.942 & 0.084& 0.957 & 0.0905 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &       &&&       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.4   & 0.975 & 645 & 0.952 & 552   & 0.954 & 577  & 0.918 & 510 & 0.953 & 571 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.4   & 0.920  & 649   & 0.952 & 728   & 0.93  & 692& 0.914 & 668   & 0.950  & 736 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI70modcorr1000}\n\\end{sidewaystable}\n\n\n\n\n\\begin{sidewaystable}[h]\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 30\\% non-compliance, high correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{lcrrrrrrrrrrrrr} \\hline\n  \n    \\textbf{} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}} &  \\multicolumn{2}{c}{\\textbf{2sls}} &  \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}} &\\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n    \\textbf{Cost distribution} & \\textbf{} & \\textbf{$\\rho$}   & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width} & \\textbf{coverage} & \\textbf{width}& \\textbf{coverage} & \\textbf{width} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &    &&   &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   & 0.954 & 0.113  & 0.954 & 0.113 & 0.984 & 0.299 &&& 0.987 & 0.299 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.949 & 0.112  &  0.949 & 0.112 & 0.992 & 0.324 & &&0.986 & 0.295 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   &  0.951 & 0.229&  0.951 & 0.229 & 0.985 & 0.148 & &&0.958 & 0.122 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.946 & 0.228 &  0.946 & 0.228 & 0.992 & 0.162 & &&0.952 & 0.121 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   &  0.999 & 408   &  0.953 & 207   & 0.998 & 373   & &&0.990  & 279 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.867 & 407&  0.947 & 533   & 0.93  & 514   & &&0.957 & 585 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   &  0.952 & 0.113&  0.952 & 0.113 & 0.947 & 0.764 & 0.922 & 0.681 &0.961 & 0.822 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.947 & 0.113&  0.947 & 0.113 & 0.954 & 0.825 &  0.947 & 0.820 &0.951 & 0.817 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   &  0.955 & 0.757&  0.955 & 0.757 & 0.986 & 0.152 & 0.928 & 0.109 & 0.957 & 0.123 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.946 & 0.757&  0.946 & 0.757 & 0.99  & 0.162 & 0.950 & 0.121&0.954 & 0.123 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8 & 0.999 & 828  &  0.955 & 539   & 0.99  & 707& 0.942 & 528   & 0.966 & 596 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.884 & 831&  0.945 & 1041  & 0.901 & 920 & 0.882 & 902  & 0.95  & 1118 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{Gaussian} & \\textbf{} & 0.8   &  0.954 & 0.113  &  0.954 & 0.113 & 0.948 & 0.894& 0.836 & 0.745 & 0.961 & 0.956 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.951 & 0.113&  0.951 & 0.113 & 0.961 & 0.956& 0.826 & 0.750 & 0.955 & 0.938 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   &  0.954 & 0.883&  0.954 & 0.883 & 0.989 & 0.154 & 0.900 & 0.108& 1     & 0.204 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.953 & 0.884&  0.953 & 0.884 & 0.993 & 0.163  & 0.916 & 0.108& 1     & 0.204 \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\textbf{} & \\textbf{} & 0.8   & 0.994 & 947&  0.952 & 674   & 0.978 & 825 & 0.837 & 591  & 0.990  & 877 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.893 & 948 &  0.953 & 1155  & 0.910  & 1042 & 0.842 & 993 & 0.969 & 1307 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI30highcorr}\n\\end{sidewaystable}\n\n\n\\begin{sidewaystable}[h]\n\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 30\\% non-compliance, high correlation between outcomes and sample size $n=1000$.uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n    \n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}} &  \\multicolumn{2}{c}{\\textbf{2sls}}&  \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}&\\multicolumn{2}{c}{\\textbf{uBGN}}  & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n    \\multicolumn{1}{c}{\\textbf{Cost distribution}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\textbf{coverage} & \\textbf{width}\\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   &  0.943 & 0.036&  0.943 & 0.036 & 0.985 & 0.089 &&& 0.951 & 0.074 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  &  0.952 & 0.036&  0.952 & 0.036 & 0.996 & 0.097 & &&0.955 & 0.074 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   &  0.949 & 0.072 &  0.949 & 0.072 & 0.988 & 0.044 & &&0.938 & 0.035 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  &  0.954 & 0.072 &  0.954 & 0.072 & 0.992 & 0.048 & &&0.951 & 0.036 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8 & 1     & 129  &  0.95  & 65.4  & 1     & 112   & &&0.946 & 66.3 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.864 & 129  & 0.952 & 168.4 & 0.928 & 154   &&& 0.946 & 170.2 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8    & 0.948 & 0.036 & 0.948 & 0.036 & 0.938 & 0.230 & 0.897 & 0.199  & 0.944 & 0.239 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.952 & 0.036  & 0.952 & 0.036 & 0.955 & 0.249& 0.896 & 0.202 & 0.950  & 0.241 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.946 & 0.240& 0.946 & 0.240  & 0.983 & 0.045& 0.921 & 0.032 & 0.946 & 0.035\\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.949 & 0.240& 0.949 & 0.240  & 0.990  & 0.048 & 0.925 & 0.032& 0.950  & 0.036 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8& 0.996 & 263     & 0.950  & 172   & 0.982 & 213 & 0.928 & 153  & 0.948 & 172 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8 & 0.883 & 263   & 0.946 & 329   & 0.899 & 277 & 0.898 & 275  & 0.946 & 330 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost}&& &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.8    & 0.950  & 0.0356   & 0.95  & 0.0356 & 0.936 & 0.271 &  0.684 & 0.217&0.942 & 0.279 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.944 & 0.0356 & 0.944 & 0.0356 & 0.955 & 0.290& 0.701 & 0.221  & 0.950  & 0.280 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   &  0.946 & 0.283&  0.946 & 0.283 & 0.986 & 0.0457 & 0.833 & 0.032 & 0.964 & 0.038 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.952 & 0.283& 0.952 & 0.283 & 0.990  & 0.048& 0.849 & 0.032 & 0.965 & 0.038 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &   &&    &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8  & 0.994 & 303    & 0.952 & 218   & 0.972 & 250 & 0.722 & 173  & 0.954 & 221 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.89  & 302  & 0.947 & 367   & 0.904 & 315 & 0.722 & 292  & 0.946 & 364 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI30highcorr1000}\n\\end{sidewaystable}\n\n\n\\begin{sidewaystable}[h]\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70\\% non-compliance, high correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n   \n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}}& \\multicolumn{2}{c}{\\textbf{2sls}}& \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}  & \\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n    \\multicolumn{1}{c}{\\textbf{Cost distribution}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\textbf{coverage} & \\textbf{width}\\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &    &&   &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.97  & 0.269& 0.97  & 0.269 & 0.982 & 1.29  &&& 0.988 & 1.09 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.966 & 0.272& 0.966 & 0.272 & 0.99  & 1.36  & &&0.988 & 1.07 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.972 & 0.546& 0.972 & 0.546 & 0.982 & 0.64  & &&0.966 & 0.443 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8 & 0.970  & 0.550  &0.970  & 0.550  & 0.989 & 0.662&& & 0.960  & 0.446 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &       &&&       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8& 1     & 975      & 0.973 & 495   & 1     & 1322  & &&0.993 & 1032 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8 & 0.875 & 981      & 0.966 & 1284  & 0.936 & 1858  & &&0.957 & 2096 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8    & 0.969 & 0.268 & 0.969 & 0.268 & 0.95  & 2.51 &  0.921 & 1.82 & 0.967 & 2.77 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.966 & 0.272 & 0.966 & 0.272 & 0.965 & 2.75& 0.904 & 1.88  & 0.964 & 2.80 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} & &&      &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8     & 0.967 & 1.68& 0.967 & 1.68  & 0.984 & 0.609 & 0.935 & 0.315& 0.967 & 0.430 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.965 & 1.70 & 0.965 & 1.70   & 0.989 & 0.626& 0.930 & 0.324 & 0.958 & 0.440 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &    &&   &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8    & 1     & 1871 & 0.963 & 1175  & 0.992 & 2233& 0.947 & 1397  & 0.975 & 1964 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.895 & 1885   & 0.965 & 2383  & 0.908 & 3096& 0.903 & 2631  & 0.954 & 3867 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.8   & 0.963 & 0.271& 0.963 & 0.271 & 0.947 & 2.92& 0.839 & 2.03  & 0.966 & 3.42 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.973 & 0.27& 0.973 & 0.270  & 0.966 & 3.05  & 0.855 & 2.03 & 0.968 & 3.37 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &       &       &  &&     &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   &  0.96  & 1.92 &  0.96  & 1.92  & 0.983 & 0.645& 0.906 & 0.322  & 0.999 & 0.789 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.964 & 1.91 & 0.964 & 1.91  & 0.99  & 0.631& 0.918 & 0.325 & 0.999 & 0.774 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &      && &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.998 & 2091  & 0.958 & 1417  & 0.981 & 2654 & 0.863 & 1586 & 0.990  & 3145 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.902 & 2075     & 0.966 & 2568  & 0.912 & 3389 & 0.866 & 2755 & 0.979 & 4819 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI70highcorr}\n\\end{sidewaystable}\n\n\n\\begin{sidewaystable}[h]\n  \\centering\n  \\caption{CI Coverage rates and median width for incremental Cost, QALYs, and INB, across scenarios with 70\\% non-compliance, high correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data.}\n    \\begin{tabular}{rcrrrrrrrrrrr} \\hline\n\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{}}  & \\multicolumn{2}{c}{\\textbf{2sls}}& \\multicolumn{2}{c}{\\textbf{3sls}} & \\multicolumn{2}{c}{\\textbf{uBN}}& \\multicolumn{2}{c}{\\textbf{uBGN}} & \\multicolumn{2}{c}{\\textbf{BFL}} \\\\ \\cline{4-13}\n    \\multicolumn{1}{c}{\\textbf{Cost distribution}} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\multicolumn{1}{c}{\\textbf{coverage}} & \\multicolumn{1}{c}{\\textbf{width}} & \\textbf{coverage} & \\textbf{width}\\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Normal}} & \\textbf{Cost} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8    & 0.957 & 0.083  & 0.957 & 0.083 & 0.983 & 0.211 & &&0.959 & 0.175 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.954 & 0.083 & 0.954 & 0.083 & 0.991 & 0.230  &  &&0.954 & 0.177 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &       &       &      && &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.959 & 0.169 & 0.959 & 0.169 & 0.983 & 0.106 &  &&0.951 & 0.084 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.952 & 0.169 & 0.952 & 0.169 & 0.991 & 0.115 & && 0.951 & 0.085 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &       &&&       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 1     & 302 & 0.952 & 153   & 0.999 & 269   &  &&0.952 & 158 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.873 & 302  & 0.954 & 395   & 0.931 & 369   && & 0.953 & 406 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Gamma}} & \\textbf{Cost} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   & 0.958 & 0.0833& 0.958 & 0.0833 & 0.938 & 0.514 &0.890 & 0.442 &  0.948 & 0.535 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.951 & 0.0832& 0.951 & 0.0832 & 0.954 & 0.556 &  0.904 & 0.449& 0.949 & 0.542 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &       &       &     &&  &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8  & 0.952 & 0.527 & 0.952 & 0.527 & 0.986 & 0.108 & 0.923 & 0.076& 0.952 & 0.0841 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.95  & 0.525 & 0.95  & 0.525 & 0.992 & 0.115 & 0.930 & 0.077 &0.947 & 0.0843 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &       &       &      && &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8    & 0.998 & 583  & 0.953 & 368   & 0.986 & 479 & 0.923 & 336  & 0.950  & 374 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8    & 0.888 & 582 & 0.953 & 734   & 0.902 & 627   & 0.904 & 627 & 0.951 & 753 \\\\ \\hline\n    \\multicolumn{1}{l}{\\textbf{Inverse}} & \\textbf{Cost}&& &       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{Gaussian}} & \\textbf{} & 0.8    & 0.948 & 0.083  & 0.948 & 0.083 & 0.938 & 0.583 & 0.785 & 0.474& 0.946 & 0.602 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  &  0.956 & 0.083&  0.956 & 0.083 & 0.962 & 0.63& 0.786 & 0.482  & 0.955 & 0.604 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{QALYs} &&&       &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8   &  0.952 & 0.599&  0.952 & 0.599 & 0.992 & 0.109 & 0.891 & 0.076& 0.96  & 0.091 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8  & 0.959 & 0.600    & 0.959 & 0.600   & 0.992 & 0.115 &  0.896 & 0.077&0.968 & 0.091 \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{INB} &  &&     &       &       &       &       &       &       &       &  \\\\ \\cline{2-13}\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & 0.8 & 0.996 & 650  &  0.946 & 447   & 0.978 & 542 & 0.800& 370  & 0.955 & 468 \\\\\n    \\multicolumn{1}{l}{\\textbf{}} & \\textbf{} & -0.8   & 0.899 & 650 & 0.96  & 801   & 0.915 & 694   & 0.806 & 654& 0.958 & 807 \\\\ \\hline\n    \\end{tabular}\n  \\label{CI70highcorr1000}\n\\end{sidewaystable}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 30\\% non-compliance, high correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n\n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls  (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}}& \\multicolumn{1}{c}{\\textbf{uBGN}} & \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &  0.029 & 0.060 && 0.060\\\\\n    \\textbf{} & \\textbf{} & -0.8 & 0.029 & 0.061 & &0.060\\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.059 & 0.030 & &0.030 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.059 & 0.030 & &0.030 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8     & 54 & 55   & &56 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 137 & 140   & &139 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.029 & 0.196 & 0.194& 0.196 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.029 & 0.200 & 0.205  & 0.200 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.192 & 0.030  & 0.030& 0.030 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.196 & 0.030& 0.030 & 0.030 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8      & 138   & 141  & 137 & 141 \\\\\n    \\textbf{} & \\textbf{} & -0.8     & 271   & 276& 281   & 276 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.8  & 0.029 & 0.229 & 0.272& 0.229 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.029 & 0.228 & 0.272& 0.228 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &  0.226 & 0.030 & 0.032& 0.030 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  0.225 & 0.029& 0.031 & 0.029 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &  175   & 178 &210  & 178 \\\\\n    \\textbf{} & \\textbf{} & -0.8     & 291   & 296 &345  & 296 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse30N100_high}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 30\\% non-compliance, moderate correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n    \n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}}& \\multicolumn{1}{c}{\\textbf{uBGN}} & \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.009 & 0.018 && 0.018 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.009 & 0.018 & &0.018 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.018 & 0.009 & &0.009 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.018 & 0.009 & &0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 26    & 26    & &26 \\\\\n    \\textbf{} & \\textbf{} & -0.4    & 38  & 38  && 39 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.009 & 0.061 &0.061& 0.061 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.009 & 0.061 &0.061& 0.061 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.061 & 0.009 & 0.009&0.009 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.061 & 0.009 & 0.009& 0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4     & 55 & 55& 56  & 55\\\\\n    \\textbf{} & \\textbf{} & -0.4    & 75  & 75 &76 & 75 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.4    & 0.009 & 0.072 &0.075& 0.072 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.009 & 0.072 & 0.076&0.073 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.072 & 0.009& 0.035 & 0.009 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.072 & 0.009 &  0.035&0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4     & 66  & 66  &69& 66 \\\\\n    \\textbf{} & \\textbf{} & -0.4    & 85  & 86  &89& 86 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse30N1000}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 30\\% non-compliance, high correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n \n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}} & \\multicolumn{1}{c}{\\textbf{uBGN}}& \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.009 & 0.019 &&0.019 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.009 & 0.018 & &0.018 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.019 & 0.009 & &0.009 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.018 & 0.009 & &0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8     & 17  & 17  & &17 \\\\\n    \\textbf{} & \\textbf{} & -0.8    & 43 & 43  & &44 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.009 & 0.062  & 0.061& 0.062 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.009 & 0.062 & 0.062 & 0.062 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.062 & 0.009 & 0.009& 0.009\\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.062 & 0.009 & 0.009& 0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8     & 44  & 44& 43 & 44 \\\\\n    \\textbf{} & \\textbf{} & -0.8    & 85  & 85   & 84& 85 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.8   & 0.009 & 0.073& 0.105 & 0.073 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &0.009 & 0.072& 0.103 & 0.072 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.073 & 0.009 & 0.011& 0.009 \\\\\n    \\textbf{} & \\textbf{} & -0.8 & 0.072 & 0.009 & 0.011& 0.009 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 56 & 56 & 80 & 56\\\\\n    \\textbf{} & \\textbf{} & -0.8  & 94  & 94& 132  & 94 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse30N1000_high}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 70\\% non-compliance, moderate correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n   \n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}} & \\multicolumn{1}{c}{\\textbf{uBGN}}& \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &0.074 & 0.207 && 0.181 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.074 & 0.203 && 0.182 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.145 & 0.104 & &0.089 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.146 & 0.109 & &0.088 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 212   & 272   & &264 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  309   & 396   & &383 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.072 & 0.565 & 0.682& 0.559 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.073 & 0.553& 0.636 & 0.549 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.467 & 0.097& 0.082 & 0.085 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.456 & 0.099 & 0.083& 0.086 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4      & 426   & 520 &429  & 500 \\\\\n    \\textbf{} & \\textbf{} & -0.4     & 570   & 697 &758  & 687 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.4   & 0.073 & 0.622  & 0.946& 0.622 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.074 & 0.635& 1.096 & 0.635 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   &  0.521 & 0.094  & 0.092& 0.094 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  0.516 & 0.092 & 0.110& 0.092 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 484   & 583  & 632 & 583 \\\\\n    \\textbf{} & \\textbf{} & -0.4  &  630   & 865 & 967  & 865 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse70N100}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 70\\% non-compliance, high correlation between outcomes and sample size $n=100$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n    \n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}} & \\multicolumn{1}{c}{\\textbf{uBGN}}& \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.072 & 0.201& & 0.180 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.075 & 0.209 && 0.182 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n   \\textbf{} & \\textbf{} & 0.8   & 0.147 & 0.100 && 0.086 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.147 & 0.109 && 0.090 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 131   & 169   & &169 \\\\\n    \\textbf{} & \\textbf{} & -0.8     & 351   & 447   && 425 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.072 & 0.543 & 0.604 &0.531 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.073 & 0.546 & 0.563&0.538 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8     & 0.450  & 0.097  & 0.081& 0.086 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.454 & 0.096 & 0.084 & 0.086\\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8     & 313   & 377& 429   & 368 \\\\\n    \\textbf{} & \\textbf{} & -0.8    & 638   & 768&758   & 773 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.8    & 0.074 & 0.637 & 0.902& 0.637 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.074  & 0.635 & 1.010 & 0.635 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.532 & 0.092 & 0.100& 0.092 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.526 & 0.092 & 0.096& 0.092 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 395   & 468 & 615  & 468 \\\\\n    \\textbf{} & \\textbf{} & -0.8     & 704   & 865  &1022 & 865 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse70N100_high}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 70\\% non-compliance, moderate correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n   \n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}}& \\multicolumn{1}{c}{\\textbf{uBGN}} & \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.022 & 0.043 && 0.043 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.022 & 0.043 && 0.043 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4    & 0.043 & 0.022 & &0.022 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.043 & 0.022 & &0.022 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4    & 61  & 62  & &62 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 90  & 91  & &91 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.021 & 0.135 & 0.138& 0.136 \\\\\n    \\textbf{} & \\textbf{} & -0.4 & 0.021 & 0.135& 0.138 & 0.135 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.135 & 0.021& 0.021 & 0.021 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.134 & 0.021& 0.021 & 0.021 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4      & 124   & 169& 126   & 125 \\\\\n    \\textbf{} & \\textbf{} & -0.4     & 168   & 169 &172& 170 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.4  & 0.021 & 0.153 & 0.158 & 0.153 \\\\\n    \\textbf{} & \\textbf{} & -0.4   & 0.021 & 0.153  & 0.158& 0.153 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4   & 0.151 & 0.022& 0.022 & 0.022 \\\\\n    \\textbf{} & \\textbf{} & -0.4  & 0.152 & 0.022& 0.022 & 0.022 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.4      & 141   & 142  &147 & 142 \\\\\n    \\textbf{} & \\textbf{} & -0.4     & 185   & 187   & 193&187 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse70N1000}\n\\end{table}\n\n\n\n\\begin{table}[h]\n  \\centering\n  \\caption{RMSE for incremental Cost, QALYs and INB across scenarios with 70\\% non-compliance, high correlation between outcomes and sample size $n=1000$. uBGN was not applied in settings with normal cost data. Numbers for INB have been rounded to the nearest integer.}\n    \\begin{tabular}{lcrrrrr} \\hline\n\n    \\textbf{Cost distribution} & \\textbf{} & \\multicolumn{1}{c}{\\textbf{$\\rho$}}  & \\multicolumn{1}{c}{\\textbf{3sls (2sls)}} & \\multicolumn{1}{c}{\\textbf{uBN}}& \\multicolumn{1}{c}{\\textbf{uBGN}} & \\multicolumn{1}{c}{\\textbf{BFL}} \\\\ \\hline\n    \\textbf{Normal} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &0.021 & 0.043 & &0.043 \\\\\n    \\textbf{} & \\textbf{} & -0.8 & 0.021 & 0.043 & &0.043 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.043 & 0.021 & &0.021 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.043 & 0.022 & &0.021 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &  39    & 39  & &39\\\\\n    \\textbf{} & \\textbf{} & -0.8  &  100   & 101 && 101 \\\\ \\hline\n    \\textbf{Gamma} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8    & 0.021 & 0.137 & 0.135 & 0.137 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.021 & 0.135  & 0.133& 0.135 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.135 & 0.022 & 0.022 & 0.021 \\\\\n    \\textbf{} & \\textbf{} & -0.8  & 0.133 & 0.021 & 0.021& 0.021 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   &  95    & 96  &94  & 96 \\\\\n    \\textbf{} & \\textbf{} & -0.8  &  187   & 188   &186& 188 \\\\ \\hline\n    \\textbf{Inverse} & \\textbf{Cost} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{Gaussian} & \\textbf{} & 0.8    & 0.021 & 0.157& 0.190 & 0.157 \\\\\n    \\textbf{} & \\textbf{} & -0.8 & 0.021 & 0.153 &0.192&0.153 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{QALYs} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8   & 0.155 & 0.021 & 0.023& 0.021 \\\\\n    \\textbf{} & \\textbf{} & -0.8   & 0.151 & 0.021& 0.023 & 0.021 \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{INB} &       &       &       &       &  \\\\ \\cline{2-7}\n    \\textbf{} & \\textbf{} & 0.8      & 118   & 119&144   & 119 \\\\\n    \\textbf{} & \\textbf{} & -0.8     & 201   & 203 &250  & 203 \\\\ \\hline\n    \\end{tabular}\n  \\label{rmse70N1000_high}\n\\end{table}\n\n\n\n\n\n\n\n\n\n\n\n", "itemtype": "equation", "pos": 26714, "prevtext": "\nwhere $p$ denotes the corresponding average non-compliance percentage expressed as a probability, i.e here $p \\in \\{0.3, 0.7\\}$.\nWe now generate, $D_i$ the random variable of treatment received as\n\n", "index": 15, "text": "\\begin{equation}\nD_i=\\begin{cases} Z_i, \\text{if\\ } s_i=0\\text{\\  or\\ } Z_i=0,\\\\\n1-Z_i, \\text{if\\ } s_i=1\n\\end{cases}\n\\end{equation}\n", "mathml": "<math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"S0.E7.m1\" class=\"ltx_Math\" alttext=\"D_{i}=\\begin{cases}Z_{i},\\text{if\\ }s_{i}=0\\text{\\ or\\ }Z_{i}=0,\\\\&#10;1-Z_{i},\\text{if\\ }s_{i}=1\\end{cases}\" display=\"block\"><mrow><msub><mi>D</mi><mi>i</mi></msub><mo>=</mo><mrow><mo>{</mo><mtable columnspacing=\"5pt\" displaystyle=\"true\" rowspacing=\"0pt\"><mtr><mtd columnalign=\"left\"><mrow><mrow><mrow><msub><mi>Z</mi><mi>i</mi></msub><mo>,</mo><mrow><mtext>if\u00a0</mtext><mo>\u2062</mo><msub><mi>s</mi><mi>i</mi></msub></mrow></mrow><mo>=</mo><mrow><mn>0</mn><mo>\u2062</mo><mtext>\u00a0or\u00a0</mtext><mo>\u2062</mo><msub><mi>Z</mi><mi>i</mi></msub></mrow><mo>=</mo><mn>0</mn></mrow><mo>,</mo></mrow></mtd><mtd/></mtr><mtr><mtd columnalign=\"left\"><mrow><mrow><mrow><mn>1</mn><mo>-</mo><msub><mi>Z</mi><mi>i</mi></msub></mrow><mo>,</mo><mrow><mtext>if\u00a0</mtext><mo>\u2062</mo><msub><mi>s</mi><mi>i</mi></msub></mrow></mrow><mo>=</mo><mn>1</mn></mrow></mtd><mtd/></mtr></mtable></mrow></mrow></math>", "type": "latex"}]